Peroxisome	B-protein
proliferator	I-protein
activator	I-protein
receptor-gamma	I-protein
agonists	O
and	O
15-deoxy-Delta	O
(	O
12	O
,	O
14	O
)	O
(	O
12	O
,	O
14	O
)	O
-PGJ	O
(	O
2	O
)	O
induce	O
apoptosis	O
in	O
normal	O
and	O
malignant	O
B-lineage	B-cell_type
cells	I-cell_type
.	O

The	O
research	O
described	O
herein	O
evaluates	O
the	O
expression	O
and	O
functional	O
significance	O
of	O
peroxisome	B-protein
proliferator	I-protein
activator	I-protein
receptor-gamma	I-protein
(	I-protein
PPAR-gamma	I-protein
)	I-protein
on	O
B-lineage	B-cell_type
cells	I-cell_type
.	O

Normal	B-cell_type
mouse	I-cell_type
B	I-cell_type
cells	I-cell_type
and	O
a	O
variety	O
of	O
B	B-cell_type
lymphoma	I-cell_type
cells	I-cell_type
reflective	O
of	O
stages	O
of	O
B	O
cell	O
differentiation	O
(	O
e.g.	O
,	O
70Z/3	O
,	O
CH31	O
,	O
WEHI-231	O
,	O
CH12	O
,	O
and	O
J558	O
)	O
express	O
PPAR-gamma	B-RNA
mRNA	I-RNA
and	O
,	O
by	O
Western	O
blot	O
analysis	O
,	O
the	O
67-kDa	B-protein
PPAR-gamma	I-protein
protein	I-protein
.	O

15-Deoxy-Delta	O
(	O
12	O
,	O
14	O
)	O
-PGJ	O
(	O
2	O
)	O
(	O
15d-PGJ	O
(	O
2	O
)	O
)	O
,	O
a	O
PPAR-gamma	O
agonist	O
,	O
has	O
a	O
dose-dependent	O
antiproliferative	O
and	O
cytotoxic	O
effect	O
on	O
normal	B-cell_type
and	I-cell_type
malignant	I-cell_type
B	I-cell_type
cells	I-cell_type
as	O
shown	O
by	O
[	O
(	O
3	O
)	O
H	O
]	O
thymidine	O
and	O
3-	O
[	O
4	O
,	O
5-dimethylthiazol-2-yl	O
]	O
-2	O
,	O
5-diphenyltetrazolium	O
bromide	O
assays	O
.	O

Only	O
PPAR-gamma	O
agonists	O
(	O
thiazolidinediones	O
)	O
,	O
and	O
not	O
PPAR-alpha	O
agonists	O
,	O
mimicked	O
the	O
effect	O
of	O
15d-PGJ	O
(	O
2	O
)	O
on	O
B-lineage	B-cell_type
cells	I-cell_type
,	O
indicating	O
that	O
the	O
mechanism	O
by	O
which	O
15d-PGJ	O
(	O
2	O
)	O
negatively	O
affects	O
B-lineage	B-cell_type
cells	I-cell_type
involves	O
in	O
part	O
PPAR-gamma	B-protein
.	O

The	O
mechanism	O
by	O
which	O
PPAR-gamma	O
agonists	O
induce	O
cytotoxicity	O
is	O
via	O
apoptosis	O
,	O
as	O
shown	O
by	O
annexin	O
V	O
staining	O
and	O
as	O
confirmed	O
by	O
DNA	O
fragmentation	O
detected	O
using	O
the	O
TUNEL	O
assay	O
.	O

Interestingly	O
,	O
addition	O
of	O
PGF	O
(	O
2alpha	O
)	O
,	O
which	O
was	O
not	O
known	O
to	O
affect	O
lymphocytes	B-cell_type
,	O
dramatically	O
attenuated	O
the	O
deleterious	O
effects	O
of	O
PPAR-gamma	O
agonists	O
on	O
B	B-cell_type
lymphomas	I-cell_type
.	O

Surprisingly	O
,	O
15d-PGJ	O
(	O
2	O
)	O
induced	O
a	O
massive	O
increase	O
in	O
nuclear	O
mitogen-activated	O
protein	O
kinase	O
activation	O
,	O
and	O
pretreatment	O
with	O
PGF	O
(	O
2alpha	O
)	O
blunted	O
the	O
mitogen-activated	O
protein	O
kinase	O
activation	O
.	O

This	O
is	O
the	O
first	O
study	O
evaluating	O
PPAR-gamma	O
expression	O
and	O
its	O
significance	O
on	O
B	B-cell_type
lymphocytes	I-cell_type
.	O

PPAR-gamma	O
agonists	O
may	O
serve	O
as	O
a	O
counterbalance	O
to	O
the	O
stimulating	O
effects	O
of	O
other	O
PGs	O
,	O
namely	O
PGE	O
(	O
2	O
)	O
,	O
which	O
promotes	O
B	O
cell	O
differentiation	O
.	O

Finally	O
,	O
the	O
use	O
of	O
PGs	O
,	O
such	O
as	O
15d-PGJ	O
(	O
2	O
)	O
,	O
and	O
synthetic	O
PPAR-gamma	O
agonists	O
to	O
induce	O
apoptosis	O
in	O
B-lineage	B-cell_type
cells	I-cell_type
may	O
lead	O
to	O
the	O
development	O
of	O
novel	O
therapies	O
for	O
fatal	B-cell_type
B	I-cell_type
lymphomas	I-cell_type

Bioéende	NULL
,	NULL
Boldly	NULL
GolnVivo	NULL
``	NULL
``	NULL
Peroxisome	NULL
Proliferator	NULL
Act'ﬁlﬁr	NULL
1ﬁeceptor-y	NULL
t	NULL
Ax	NULL
eJournal	NULL
o	NULL
R	NULL
U*	NULL
Immunolo	NULL
gy	NULL
Agonists	NULL
and	NULL
15-Deoxy-	NULL
AlZ	NULL
-PGJ	NULL
;	NULL
,	NULL
Induce	NULL
Apoptosis	NULL
in	NULL
Normal	NULL
and	NULL
Malignant	NULL
B-Lineage	NULL
Cells	NULL
This	NULL
information	NULL
is	NULL
current	NULL
as	NULL
of	NULL
May	NULL
10	NULL
,	NULL
2019	NULL
.	NULL

Josué	NULL
Padilla	NULL
,	NULL
Kuljeet	NULL
Kaur	NULL
,	NULL
H.	NULL
James	NULL
Cao	NULL
,	NULL
Terry	NULL
J.	NULL
Smith	NULL
and	NULL
Richard	NULL
P.	NULL
Phipps	NULL
J	NULL
Immunol	NULL
2000	NULL
;	NULL
165:6941-6948	NULL
;	NULL
;	NULL
doi	NULL
:	NULL
10.4049/jimmunol.165.12.6941	NULL
http	NULL
:	NULL
//www.jimmunol.org/content/165/12/6941	NULL
References	NULL
_	NULL
This	NULL
article	NULL
cites	NULL
36	NULL
articles	NULL
,	NULL
20	NULL
of	NULL
which	NULL
you	NULL
can	NULL
access	NULL
for	NULL
free	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www	NULL
.	NULL

full	NULL
#	NULL
ref-list-	NULL
1	NULL
Why	NULL
The	NULL
JT	NULL
?	NULL

Submit	NULL
online	NULL
.	NULL

«	NULL
Rapid	NULL
Reviews	NULL
!	NULL

30	NULL
days*	NULL
from	NULL
submission	NULL
to	NULL
initial	NULL
decision	NULL
*e	NULL
No	NULL
Triage	NULL
!	NULL

Every	NULL
submission	NULL
reviewed	NULL
by	NULL
practicing	NULL
scientists	NULL
*	NULL
Fast	NULL
Publication	NULL
!	NULL

4	NULL
weeks	NULL
from	NULL
acceptance	NULL
to	NULL
publication	NULL
*average	NULL
Subscription	NULL
_	NULL
Information	NULL
about	NULL
subscribing	NULL
to	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
is	NULL
online	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//jimmunol.org/subscription	NULL
Permissions	NULL
_	NULL
Submit	NULL
copyright	NULL
permission	NULL
requests	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//www.aai.org/About/Publications/Jl/copyright.html	NULL
Email	NULL
Alerts	NULL
_	NULL
Receive	NULL
free	NULL
email-alerts	NULL
when	NULL
new	NULL
articles	NULL
cite	NULL
this	NULL
article	NULL
.	NULL

Sign	NULL
up	NULL
at	NULL
:	NULL
http	NULL
:	NULL
//jimmunol.org/alerts	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
is	NULL
published	NULL
twice	NULL
each	NULL
month	NULL
by	NULL
The	NULL
American	NULL
Association	NULL
of	NULL
Immunologists	NULL
,	NULL
Inc.	NULL
,	NULL
1451	NULL
Rockville	NULL
Pike	NULL
,	NULL
Suite	NULL
650	NULL
,	NULL
Rockville	NULL
,	NULL
MD	NULL
20852	NULL
Copyright	NULL
©	NULL
2000	NULL
by	NULL
The	NULL
American	NULL
Association	NULL
of	NULL
Immunologists	NULL
All	NULL
rights	NULL
reserved	NULL
.	NULL

Print	NULL
ISSN	NULL
:	NULL
0022-1767	NULL
Online	NULL
ISSN	NULL
:	NULL
1550-6606	NULL
.	NULL

6107	NULL
'Ot	NULL
Aept	NULL
uo	NULL
1san3	NULL
4g	NULL
/810founwrurt	NULL
[	NULL
'mmmy	NULL
,	NULL
/	NULL
:	NULL
dyy	NULL
wos	NULL
Peroxisome	NULL
Proliferator	NULL
Activator	NULL
Receptor-y	NULL
Agonists	NULL
and	NULL
15-Deoxy-A	NULL
``	NULL
*	NULL
``	NULL
``	NULL
-PGJ	NULL
;	NULL
,	NULL
Induce	NULL
Apoptosis	NULL
in	NULL
Normal	NULL
and	NULL
Malignant	NULL
B-Lineage	NULL
Cells	NULL
!	NULL

Josué	NULL
Padilla	NULL
,	NULL
*	NULL
``	NULL
``	NULL
Kuljeet	NULL
Kaur	NULL
,	NULL
*	NULL
H.	NULL
James	NULL
Cao	NULL
,	NULL
``	NULL
Terry	NULL
J.	NULL
Smith	NULL
,	NULL
!	NULL

and	NULL
Richard	NULL
P.	NULL
The	NULL
research	NULL
described	NULL
herein	NULL
evaluates	NULL
the	NULL
expression	NULL
and	NULL
functional	NULL
significance	NULL
of	NULL
peroxisome	NULL
proliferator	NULL
activator	NULL
receptor-y	NULL
(	NULL
PPAR-y	NULL
)	NULL
on	NULL
B-lineage	NULL
cells	NULL
.	NULL

Normal	NULL
mouse	NULL
B	NULL
cells	NULL
and	NULL
a	NULL
variety	NULL
of	NULL
B	NULL
lymphoma	NULL
cells	NULL
reflective	NULL
of	NULL
stages	NULL
of	NULL
B	NULL
cell	NULL
differentiation	NULL
(	NULL
e.g	NULL
.	NULL

,	NULL
702/3	NULL
,	NULL
CH31	NULL
,	NULL
WEHI-231	NULL
,	NULL
CH12	NULL
,	NULL
and	NULL
J558	NULL
)	NULL
express	NULL
PPAR-y	NULL
mRNA	NULL
and	NULL
,	NULL
by	NULL
Western	NULL
blot	NULL
analysis	NULL
,	NULL
the	NULL
67-kDa	NULL
PPAR-y	NULL
protein	NULL
.	NULL

15-Deoxy-A	NULL
``	NULL
``	NULL
``	NULL
-PGJ	NULL
;	NULL
,	NULL
(	NULL
15d-PGJ	NULL
;	NULL
,	NULL
)	NULL
,	NULL
a	NULL
PPAR-y	NULL
agonist	NULL
,	NULL
has	NULL
a	NULL
dose-dependent	NULL
antiproliferative	NULL
and	NULL
cytotoxic	NULL
effect	NULL
on	NULL
normal	NULL
and	NULL
malignant	NULL
B	NULL
cells	NULL
as	NULL
shown	NULL
by	NULL
[	NULL
H	NULL
]	NULL
thymidine	NULL
and	NULL
3-	NULL
[	NULL
4,5-dimethylthiazol-2-yl	NULL
}	NULL
-2,5-diphenyltetrazolium	NULL
bromide	NULL
as-says	NULL
.	NULL

Only	NULL
PPAR-y	NULL
agonists	NULL
(	NULL
thiazolidinediones	NULL
)	NULL
,	NULL
and	NULL
not	NULL
PPAR-	NULL
«	NULL
agonists	NULL
,	NULL
mimicked	NULL
the	NULL
effect	NULL
of	NULL
15d-PGJ	NULL
;	NULL
,	NULL
on	NULL
B-lineage	NULL
cells	NULL
,	NULL
indicating	NULL
that	NULL
the	NULL
mechanism	NULL
by	NULL
which	NULL
15d-PGJ	NULL
;	NULL
,	NULL
negatively	NULL
affects	NULL
B-lineage	NULL
cells	NULL
involves	NULL
in	NULL
part	NULL
PPAR-y	NULL
.	NULL

The	NULL
mechanism	NULL
by	NULL
which	NULL
PPAR-y	NULL
agonists	NULL
induce	NULL
cytotoxicity	NULL
is	NULL
via	NULL
apoptosis	NULL
,	NULL
as	NULL
shown	NULL
by	NULL
annexin	NULL
V	NULL
staining	NULL
and	NULL
as	NULL
confirmed	NULL
by	NULL
DNA	NULL
fragmentation	NULL
detected	NULL
using	NULL
the	NULL
TUNEL	NULL
assay	NULL
.	NULL

Interestingly	NULL
,	NULL
addition	NULL
of	NULL
PGF	NULL
,	NULL
,	NULL
,	NULL
,	NULL
which	NULL
was	NULL
not	NULL
known	NULL
to	NULL
affect	NULL
lymphocytes	NULL
,	NULL
dramatically	NULL
attenuated	NULL
the	NULL
deleterious	NULL
effects	NULL
of	NULL
PPAR-y	NULL
agonists	NULL
on	NULL
B	NULL
lymphomas	NULL
.	NULL

Surprisingly	NULL
,	NULL
15d-PGJ	NULL
;	NULL
,	NULL
induced	NULL
a	NULL
massive	NULL
increase	NULL
in	NULL
nuclear	NULL
mitogen-activated	NULL
protein	NULL
kinase	NULL
activation	NULL
,	NULL
and	NULL
pretreatment	NULL
with	NULL
PGF	NULL
,	NULL
,	NULL
,	NULL
blunted	NULL
the	NULL
mitogen-activated	NULL
protein	NULL
kinase	NULL
activation	NULL
.	NULL

This	NULL
is	NULL
the	NULL
first	NULL
study	NULL
evaluating	NULL
PPAR-y	NULL
expression	NULL
and	NULL
its	NULL
significance	NULL
on	NULL
B	NULL
lymphocytes	NULL
.	NULL

PPAR-y	NULL
agonists	NULL
may	NULL
serve	NULL
as	NULL
a	NULL
counterbalance	NULL
to	NULL
the	NULL
stimulating	NULL
effects	NULL
of	NULL
other	NULL
PGs	NULL
,	NULL
namely	NULL
PGE	NULL
,	NULL
,	NULL
which	NULL
promotes	NULL
B	NULL
cell	NULL
differentiation	NULL
.	NULL

Finally	NULL
,	NULL
the	NULL
use	NULL
of	NULL
PGs	NULL
,	NULL
such	NULL
as	NULL
15d-PGJ	NULL
;	NULL
,	NULL
,	NULL
and	NULL
synthetic	NULL
PPAR-y	NULL
agonists	NULL
to	NULL
induce	NULL
apoptosis	NULL
in	NULL
B-lineage	NULL
cells	NULL
may	NULL
lead	NULL
to	NULL
the	NULL
development	NULL
of	NULL
novel	NULL
therapies	NULL
for	NULL
fatal	NULL
B	NULL
lymphomas	NULL
.	NULL

The	NULL
Journal	NULL
of	NULL
Immunology	NULL
,	NULL
2000	NULL
,	NULL
165	NULL
:	NULL
6941-6948.	NULL
rostaglandin	NULL
D	NULL
;	NULL
,	NULL
is	NULL
the	NULL
major	NULL
metabolite	NULL
of	NULL
arachidonic	NULL
acid	NULL
secreted	NULL
by	NULL
mast	NULL
cells	NULL
(	NULL
1	NULL
)	NULL
and	NULL
is	NULL
a	NULL
major	NULL
product	NULL
of	NULL
macrophages	NULL
(	NULL
2	NULL
)	NULL
.	NULL

PGD	NULL
,	NULL
is	NULL
the	NULL
major	NULL
PG	NULL
synthesized	NULL
by	NULL
bone	NULL
marrow	NULL
(	NULL
3	NULL
,	NULL
4	NULL
)	NULL
.	NULL

It	NULL
readily	NULL
undergoes	NULL
dehydration	NULL
in	NULL
vivo	NULL
and	NULL
in	NULL
vitro	NULL
to	NULL
additional	NULL
,	NULL
biologically	NULL
active	NULL
PGs	NULL
of	NULL
the	NULL
J	NULL
;	NULL
,	NULL
series	NULL
(	NULL
5	NULL
)	NULL
.	NULL

Metabolites	NULL
of	NULL
the	NULL
J	NULL
,	NULL
series	NULL
have	NULL
their	NULL
own	NULL
unique	NULL
spectrum	NULL
of	NULL
biological	NULL
activities	NULL
,	NULL
including	NULL
inhibition	NULL
of	NULL
cell	NULL
cycle	NULL
progression	NULL
,	NULL
suppression	NULL
of	NULL
viral	NULL
replication	NULL
,	NULL
induction	NULL
of	NULL
heat	NULL
shock	NULL
pro-teins	NULL
,	NULL
and	NULL
stimulation	NULL
of	NULL
osteogenesis	NULL
(	NULL
5	NULL
)	NULL
.	NULL

While	NULL
PGD	NULL
,	NULL
as	NULL
well	NULL
as	NULL
other	NULL
PGs	NULL
signal	NULL
cells	NULL
through	NULL
G	NULL
protein-coupled	NULL
receptors	NULL
(	NULL
6	NULL
)	NULL
,	NULL
the	NULL
PGJ	NULL
,	NULL
;	NULL
,	NULL
series	NULL
is	NULL
actively	NULL
incorporated	NULL
into	NULL
the	NULL
nucleus	NULL
and	NULL
associates	NULL
with	NULL
nuclear	NULL
proteins	NULL
by	NULL
unknown	NULL
mechanisms	NULL
(	NULL
7	NULL
)	NULL
.	NULL

15-Deoxy-A'*	NULL
``	NULL
*-PGJ	NULL
,	NULL
(	NULL
15d-PGJ	NULL
;	NULL
,	NULL
)	NULL
°	NULL
is	NULL
the	NULL
final	NULL
metabolite	NULL
of	NULL
*University	NULL
of	NULL
Rochester	NULL
Cancer	NULL
Center	NULL
and	NULL
Departments	NULL
of	NULL
Microbiology	NULL
and	NULL
Immunology	NULL
,	NULL
*Pediatrics	NULL
,	NULL
Environmental	NULL
Medicine	NULL
,	NULL
and	NULL
``	NULL
Periodontology	NULL
,	NULL
Eastman	NULL
Department	NULL
of	NULL
Dentistry	NULL
,	NULL
Rochester	NULL
,	NULL
NY	NULL
14642	NULL
;	NULL
and	NULL
``	NULL
Division	NULL
of	NULL
Molecular	NULL
Medicine	NULL
,	NULL
University	NULL
of	NULL
California	NULL
,	NULL
Los	NULL
Angeles	NULL
School	NULL
of	NULL
Medicine	NULL
,	NULL
Harbor-University	NULL
of	NULL
California	NULL
Los	NULL
Angeles	NULL
Medical	NULL
Center	NULL
,	NULL
Torrance	NULL
,	NULL
CA	NULL
90502	NULL
Received	NULL
for	NULL
publication	NULL
March	NULL
7	NULL
,	NULL
2000	NULL
.	NULL

Accepted	NULL
for	NULL
publication	NULL
September	NULL
20	NULL
,	NULL
2000	NULL
.	NULL

The	NULL
costs	NULL
of	NULL
publication	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
the	NULL
payment	NULL
of	NULL
page	NULL
charges	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
advertisement	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

Section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL
'	NULL

This	NULL
work	NULL
was	NULL
supported	NULL
by	NULL
U.S.	NULL
Public	NULL
Health	NULL
Service	NULL
Grants	NULL
5-T32DE07061-21	NULL
,	NULL
DE11390	NULL
,	NULL
CA11198	NULL
,	NULL
HL56002	NULL
,	NULL
ESO01247	NULL
,	NULL
EYO8976	NULL
,	NULL
and	NULL
EY11708	NULL
and	NULL
a	NULL
University	NULL
of	NULL
Rochester	NULL
Cancer	NULL
Center	NULL
Discovery	NULL
Fund	NULL
Grant	NULL
.	NULL

2	NULL
Address	NULL
correspondence	NULL
and	NULL
reprint	NULL
requests	NULL
to	NULL
Dr.	NULL
Richard	NULL
P.	NULL
Phipps	NULL
,	NULL
Box	NULL
704	NULL
,	NULL
Cancer	NULL
Center	NULL
,	NULL
University	NULL
of	NULL
Rochester	NULL
School	NULL
of	NULL
Medicine	NULL
and	NULL
Dentistry	NULL
,	NULL
601	NULL
Elm-wood	NULL
Avenue	NULL
,	NULL
Rochester	NULL
,	NULL
NY	NULL
14642	NULL
.	NULL

E-mail	NULL
address	NULL
:	NULL
richard_phipps	NULL
@	NULL
urme	NULL
.	NULL

rochester.edu	NULL
°	NULL
Abbreviations	NULL
used	NULL
in	NULL
this	NULL
paper	NULL
:	NULL
15d-PGJ	NULL
;	NULL
,	NULL
15-deoxy-A	NULL
'	NULL
>	NULL
'-PGJ	NULL
;	NULL
;	NULL
PPAR-y	NULL
,	NULL
peroxisome	NULL
proliferator-activated	NULL
receptor	NULL
-y	NULL
;	NULL
MTT	NULL
,	NULL
3-	NULL
[	NULL
4,5-dimethylthiazole-2-yl	NULL
}	NULL
-2,5-diphenyltetrazolium	NULL
bromide	NULL
;	NULL
WY-14643	NULL
,	NULL
4-chloro-6-	NULL
(	NULL
2,3-xylidino	NULL
)	NULL
-2-pyrimidinylthioacetic	NULL
acid	NULL
;	NULL
PI	NULL
,	NULL
propidium	NULL
iodide	NULL
;	NULL
MAPK	NULL
,	NULL
mitogen-activated	NULL
protein	NULL
kinase	NULL
;	NULL
BdUTP	NULL
,	NULL
bromo-dUTP	NULL
.	NULL

Copyright	NULL
©	NULL
2000	NULL
by	NULL
The	NULL
American	NULL
Association	NULL
of	NULL
Immunologists	NULL
PGD	NULL
,	NULL
degradation	NULL
.	NULL

Both	NULL
15d-PGJ	NULL
;	NULL
,	NULL
and	NULL
the	NULL
antidiabetic	NULL
drugs	NULL
of	NULL
the	NULL
thiazolidinedione	NULL
class	NULL
are	NULL
potent	NULL
ligands	NULL
for	NULL
a	NULL
nuclear	NULL
hormone	NULL
receptor	NULL
known	NULL
as	NULL
peroxisome	NULL
proliferator-activated	NULL
receptor	NULL
y	NULL
(	NULL
PPAR-y	NULL
)	NULL
.	NULL

PPAR-y	NULL
is	NULL
a	NULL
member	NULL
of	NULL
a	NULL
superfamily	NULL
of	NULL
nuclear	NULL
hormone	NULL
receptors	NULL
that	NULL
function	NULL
as	NULL
ligand-dependent	NULL
transcription	NULL
factors	NULL
(	NULL
8	NULL
)	NULL
.	NULL

Three	NULL
receptor	NULL
subtypes	NULL
of	NULL
PPARs	NULL
,	NULL
termed	NULL
a	NULL
,	NULL
8	NULL
,	NULL
and	NULL
7	NULL
,	NULL
have	NULL
been	NULL
identified	NULL
.	NULL

The	NULL
transcriptional	NULL
activity	NULL
of	NULL
the	NULL
PPAR	NULL
subtypes	NULL
is	NULL
enhanced	NULL
by	NULL
a	NULL
multitude	NULL
of	NULL
chemical	NULL
compounds	NULL
,	NULL
including	NULL
fatty	NULL
acids	NULL
,	NULL
thiazolidinedione	NULL
antidiabetic	NULL
agents	NULL
,	NULL
selected	NULL
PGs	NULL
,	NULL
peroxisome	NULL
proliferators	NULL
,	NULL
and	NULL
fibrate	NULL
hypolipidemic	NULL
drugs	NULL
(	NULL
8	NULL
)	NULL
.	NULL

After	NULL
activation	NULL
,	NULL
PPARs	NULL
control	NULL
the	NULL
expression	NULL
of	NULL
genes	NULL
implicated	NULL
in	NULL
extra-	NULL
and	NULL
intracellular	NULL
lipid	NULL
metabolism	NULL
.	NULL

These	NULL
genes	NULL
encode	NULL
enzymes	NULL
involved	NULL
in	NULL
the	NULL
peroxisomal	NULL
B-oxidation	NULL
pathway	NULL
(	NULL
8	NULL
)	NULL
.	NULL

In	NULL
particular	NULL
,	NULL
PPAR-y	NULL
is	NULL
abundantly	NULL
expressed	NULL
in	NULL
adipocytes	NULL
and	NULL
functions	NULL
as	NULL
a	NULL
key	NULL
regulator	NULL
of	NULL
adipocyte	NULL
differentiation	NULL
(	NULL
9	NULL
)	NULL
.	NULL

15d-PGJ	NULL
;	NULL
,	NULL
and	NULL
thiazolidinediones	NULL
,	NULL
such	NULL
as	NULL
troglitazone	NULL
and	NULL
ciglitazone	NULL
,	NULL
bind	NULL
directly	NULL
to	NULL
PPARy	NULL
and	NULL
promote	NULL
adipogenesis	NULL
of	NULL
cultured	NULL
fibroblasts	NULL
(	NULL
9	NULL
)	NULL
.	NULL

Recently	NULL
,	NULL
the	NULL
expression	NULL
of	NULL
PPAR-y	NULL
has	NULL
been	NULL
detected	NULL
on	NULL
macrophages	NULL
,	NULL
T	NULL
cells	NULL
,	NULL
endothelial	NULL
cells	NULL
,	NULL
vascular	NULL
smooth	NULL
muscle	NULL
cells	NULL
,	NULL
and	NULL
colonic	NULL
tumor	NULL
cells	NULL
(	NULL
10-16	NULL
)	NULL
.	NULL

The	NULL
significance	NULL
and	NULL
expression	NULL
of	NULL
PPAR-y	NULL
in	NULL
the	NULL
immune-related	NULL
cells	NULL
is	NULL
poorly	NULL
understood	NULL
.	NULL

Moreover	NULL
,	NULL
there	NULL
are	NULL
no	NULL
published	NULL
data	NULL
on	NULL
PPAR	NULL
expression	NULL
by	NULL
B-lineage	NULL
cells	NULL
.	NULL

In	NULL
this	NULL
study	NULL
15d-PGJ	NULL
;	NULL
,	NULL
as	NULL
well	NULL
as	NULL
the	NULL
synthetic	NULL
thiazolidinediones	NULL
are	NULL
shown	NULL
to	NULL
be	NULL
cytotoxic	NULL
for	NULL
B	NULL
cells	NULL
and	NULL
to	NULL
induce	NULL
cell	NULL
death	NULL
in	NULL
an	NULL
apoptotic	NULL
fashion	NULL
.	NULL

The	NULL
mechanism	NULL
by	NULL
which	NULL
15d-PGJ	NULL
;	NULL
,	NULL
interacts	NULL
with	NULL
B-lineage	NULL
cells	NULL
involves	NULL
PPAR-y	NULL
.	NULL

Materials	NULL
and	NULL
Methods	NULL
Reagents	NULL
15d-PGJ	NULL
;	NULL
,	NULL
4-chloro-6-	NULL
(	NULL
2,3-xylidino	NULL
)	NULL
-2-pyrimidinylthioacetic	NULL
acid	NULL
(	NULL
WY-14643	NULL
)	NULL
,	NULL
ciglitazone	NULL
(	NULL
thiazolidinedione	NULL
)	NULL
,	NULL
and	NULL
anti-PPAR-y1,2	NULL
rabbit	NULL
polyclonal	NULL
Ab	NULL
were	NULL
purchased	NULL
from	NULL
Biomol	NULL
(	NULL
Plymouth	NULL
Meeting	NULL
,	NULL
PA	NULL
)	NULL
.	NULL

Troglitazone	NULL
(	NULL
Rezulin	NULL
,	NULL
thia-zolidinedione	NULL
)	NULL
was	NULL
a	NULL
gift	NULL
from	NULL
Parke-Davis	NULL
(	NULL
Ann	NULL
Arbor	NULL
,	NULL
MD	NULL
)	NULL
.	NULL

PGF	NULL
;	NULL
,	NULL
,	NULL
,	NULL
MTT	NULL
0022-1767/00/	NULL
$	NULL
02.00	NULL
6107	NULL
'01	NULL
Aepy	NULL
uo	NULL
isan	NULL
$	NULL
4q	NULL
310	NULL
founwurrf'mmm//	NULL
:	NULL
dyy	NULL
wo	NULL
papeojumoG	NULL
6942	NULL
and	NULL
DMSO	NULL
were	NULL
purchased	NULL
from	NULL
Sigma	NULL
(	NULL
St.	NULL
Louis	NULL
,	NULL
MO	NULL
)	NULL
.	NULL

Tri-reagent	NULL
was	NULL
obtained	NULL
from	NULL
MRC	NULL
(	NULL
Cincinnati	NULL
,	NULL
OH	NULL
)	NULL
.	NULL

Annexin	NULL
V-FITC	NULL
conjugate	NULL
was	NULL
purchased	NULL
from	NULL
Southern	NULL
Biotechnology	NULL
Associates	NULL
(	NULL
Birmingham	NULL
,	NULL
AL	NULL
)	NULL
.	NULL

Propidium	NULL
iodide	NULL
(	NULL
PT	NULL
)	NULL
was	NULL
obtained	NULL
from	NULL
Roche	NULL
(	NULL
Indianapolis	NULL
,	NULL
IN	NULL
)	NULL
.	NULL

Cell	NULL
lines	NULL
and	NULL
culture	NULL
conditions	NULL
707/3	NULL
,	NULL
ECHA4O08.1	NULL
,	NULL
WEHI-231	NULL
,	NULL
CH31	NULL
,	NULL
CH12	NULL
,	NULL
BAL-17	NULL
,	NULL
and	NULL
J558	NULL
are	NULL
clonal	NULL
B	NULL
lymphoma	NULL
cell	NULL
lines	NULL
that	NULL
reflect	NULL
stages	NULL
of	NULL
B	NULL
cell	NULL
ontogeny	NULL
and	NULL
have	NULL
been	NULL
described	NULL
in	NULL
detail	NULL
previously	NULL
(	NULL
17	NULL
,	NULL
18	NULL
)	NULL
.	NULL

Briefly	NULL
,	NULL
702/3	NULL
is	NULL
positive	NULL
for	NULL
cyto-plasmic	NULL
Ig	NULL
;	NULL
is	NULL
negative	NULL
for	NULL
expression	NULL
of	NULL
surface	NULL
Ig	NULL
,	NULL
MHC	NULL
II	NULL
,	NULL
and	NULL
FcR	NULL
;	NULL
and	NULL
is	NULL
a	NULL
model	NULL
for	NULL
pre-B	NULL
lymphocytes	NULL
.	NULL

CH31	NULL
,	NULL
WEHI-231	NULL
,	NULL
and	NULL
ECH4O8.1	NULL
are	NULL
lymphomas	NULL
that	NULL
express	NULL
surface	NULL
IgM	NULL
,	NULL
MHC	NULL
II	NULL
,	NULL
FcR	NULL
,	NULL
and	NULL
CD5	NULL
;	NULL
do	NULL
not	NULL
secrete	NULL
Ig	NULL
;	NULL
and	NULL
are	NULL
models	NULL
for	NULL
immature	NULL
B	NULL
lymphocytes	NULL
based	NULL
on	NULL
their	NULL
susceptibility	NULL
to	NULL
anti-IgM-induced	NULL
apoptosis	NULL
.	NULL

The	NULL
BAL-17	NULL
and	NULL
CH12	NULL
lymphomas	NULL
resemble	NULL
mature	NULL
B	NULL
lymphocytes	NULL
in	NULL
that	NULL
they	NULL
express	NULL
surface	NULL
IgM	NULL
,	NULL
MHC	NULL
II	NULL
,	NULL
and	NULL
FcR	NULL
but	NULL
do	NULL
not	NULL
secrete	NULL
Ig	NULL
,	NULL
nor	NULL
are	NULL
they	NULL
susceptible	NULL
to	NULL
anti-IgM-induced	NULL
apoptosis	NULL
.	NULL

J558	NULL
is	NULL
a	NULL
mouse	NULL
myeloma	NULL
that	NULL
resembles	NULL
plasma	NULL
cells	NULL
in	NULL
that	NULL
it	NULL
expresses	NULL
PC.1	NULL
,	NULL
does	NULL
not	NULL
express	NULL
surface	NULL
Ig	NULL
,	NULL
and	NULL
secretes	NULL
IgA	NULL
.	NULL

Normal	NULL
B	NULL
lymphocytes	NULL
and	NULL
lymphoma	NULL
cell	NULL
lines	NULL
were	NULL
cultured	NULL
in	NULL
RPMI	NULL
1640	NULL
(	NULL
Life	NULL
Technologies	NULL
,	NULL
Grand	NULL
Island	NULL
,	NULL
NY	NULL
)	NULL
supplemented	NULL
with	NULL
10	NULL
%	NULL
FBS	NULL
(	NULL
HyClone	NULL
,	NULL
Logan	NULL
,	NULL
UT	NULL
)	NULL
,	NULL
5	NULL
X	NULL
10~°	NULL
M	NULL
2-ME	NULL
(	NULL
Eastman	NULL
Kodak	NULL
,	NULL
Rochester	NULL
,	NULL
NY	NULL
)	NULL
,	NULL
10	NULL
mM	NULL
HEPES	NULL
(	NULL
U.S.	NULL
Biochemical	NULL
Corp.	NULL
,	NULL
Cleveland	NULL
,	NULL
OH	NULL
)	NULL
,	NULL
2	NULL
mM	NULL
L-glutamine	NULL
(	NULL
Life	NULL
Technologies	NULL
)	NULL
,	NULL
and	NULL
50	NULL
ug/ml	NULL
gentamicin	NULL
(	NULL
Life	NULL
Technologies	NULL
)	NULL
.	NULL

The	NULL
B	NULL
lymphomas	NULL
were	NULL
kept	NULL
under	NULL
the	NULL
same	NULL
culture	NULL
con-ditions	NULL
,	NULL
except	NULL
for	NULL
the	NULL
percentage	NULL
of	NULL
FBS	NULL
,	NULL
which	NULL
was	NULL
5	NULL
%	NULL
.	NULL

Normal	NULL
and	NULL
neoplastic	NULL
B	NULL
cells	NULL
and	NULL
C3H10T1/2	NULL
fibroblast-like	NULL
cells	NULL
were	NULL
preincubated	NULL
with	NULL
PPAR-y	NULL
agonists	NULL
and	NULL
non-PPAR-y	NULL
agonists	NULL
in	NULL
FBS-free	NULL
medium	NULL
for	NULL
a	NULL
period	NULL
of	NULL
not	NULL
more	NULL
than	NULL
6	NULL
h	NULL
(	NULL
19	NULL
)	NULL
.	NULL

FBS	NULL
was	NULL
then	NULL
added	NULL
at	NULL
the	NULL
percentages	NULL
indicated	NULL
above	NULL
.	NULL

When	NULL
normal	NULL
B	NULL
lymphocytes	NULL
were	NULL
used	NULL
,	NULL
the	NULL
medium	NULL
was	NULL
also	NULL
supplemented	NULL
with	NULL
IL-4	NULL
(	NULL
500	NULL
U/ml	NULL
;	NULL
Genzyme	NULL
,	NULL
Cambridge	NULL
,	NULL
MA	NULL
)	NULL
and	NULL
Escherichia	NULL
coli	NULL
LPS	NULL
(	NULL
1	NULL
ug/ml	NULL
;	NULL
Sigma	NULL
)	NULL
to	NULL
drive	NULL
their	NULL
proliferation	NULL
.	NULL

cDNA	NULL
synthesis	NULL
and	NULL
RT-PCR	NULL
for	NULL
PPAR-y	NULL
Total	NULL
RNA	NULL
was	NULL
extracted	NULL
with	NULL
Tri-Reagent	NULL
(	NULL
5	NULL
X	NULL
10°	NULL
cells/ml	NULL
)	NULL
following	NULL
the	NULL
supplier	NULL
's	NULL
protocol	NULL
.	NULL

RNA	NULL
was	NULL
solubilized	NULL
in	NULL
nuclease-free	NULL
water	NULL
by	NULL
heating	NULL
to	NULL
55°C	NULL
for	NULL
10	NULL
min	NULL
.	NULL

Two	NULL
micrograms	NULL
of	NULL
RNA	NULL
was	NULL
reversed	NULL
transcribed	NULL
using	NULL
Moloney	NULL
murine	NULL
leukemia	NULL
virus	NULL
reverse	NULL
transcriptase	NULL
(	NULL
200	NULL
U/reaction	NULL
;	NULL
Life	NULL
Technologies	NULL
,	NULL
Gaithersburg	NULL
,	NULL
MD	NULL
)	NULL
and	NULL
random	NULL
hexamers	NULL
(	NULL
18	NULL
)	NULL
.	NULL

For	NULL
each	NULL
cDNA	NULL
synthesis	NULL
reaction	NULL
,	NULL
a	NULL
parallel	NULL
reaction	NULL
was	NULL
performed	NULL
without	NULL
reverse	NULL
transcriptase	NULL
and	NULL
was	NULL
used	NULL
in	NULL
PCR	NULL
as	NULL
a	NULL
negative	NULL
control	NULL
.	NULL

PCR	NULL
reactions	NULL
for	NULL
mouse	NULL
PPAR-y	NULL
and	NULL
GAPDH	NULL
were	NULL
performed	NULL
using	NULL
Taq	NULL
DNA	NULL
polymerase	NULL
(	NULL
2.5	NULL
U	NULL
;	NULL
Roche	NULL
)	NULL
.	NULL

Mouse	NULL
PPAR-y	NULL
primers	NULL
sequences	NULL
were	NULL
5-CAAGACTACCCTTTACTGAA	NULL
and	NULL
5-CTACTTTGATCGCACTIT	NULL
GGT	NULL
.	NULL

PCR	NULL
samples	NULL
were	NULL
initially	NULL
denatured	NULL
at	NULL
94°C	NULL
for	NULL
1	NULL
min	NULL
and	NULL
then	NULL
run	NULL
for	NULL
40	NULL
cycles	NULL
(	NULL
94°C	NULL
for	NULL
45	NULL
s	NULL
,	NULL
56°C	NULL
for	NULL
45	NULL
s	NULL
,	NULL
72°C	NULL
for	NULL
1	NULL
min	NULL
)	NULL
with	NULL
a	NULL
final	NULL
extension	NULL
at	NULL
72°C	NULL
for	NULL
5	NULL
min	NULL
in	NULL
a	NULL
DNA	NULL
thermal	NULL
cycler	NULL
(	NULL
PTC-200	NULL
,	NULL
MJ	NULL
Re-search	NULL
,	NULL
Watertown	NULL
,	NULL
MA	NULL
)	NULL
.	NULL

The	NULL
identities	NULL
of	NULL
these	NULL
RT-PCR	NULL
products	NULL
were	NULL
confirmed	NULL
by	NULL
sequencing	NULL
.	NULL

No	NULL
products	NULL
were	NULL
observed	NULL
in	NULL
samples	NULL
lacking	NULL
reverse	NULL
transcriptase	NULL
.	NULL

Western	NULL
blot	NULL
for	NULL
PPAR-y	NULL
Total	NULL
proteins	NULL
were	NULL
isolated	NULL
from	NULL
all	NULL
cell	NULL
lines	NULL
using	NULL
Tri-Reagent	NULL
and	NULL
were	NULL
quantified	NULL
using	NULL
bicinchoninic	NULL
acid	NULL
protein	NULL
assay	NULL
kit	NULL
(	NULL
Pierce	NULL
,	NULL
Rockford	NULL
,	NULL
IL	NULL
)	NULL
.	NULL

Fifteen	NULL
micrograms	NULL
of	NULL
total	NULL
protein	NULL
was	NULL
fractionated	NULL
by	NULL
10	NULL
%	NULL
SDS-PAGE	NULL
and	NULL
electrophoretically	NULL
transferred	NULL
to	NULL
a	NULL
Hybond-Extra	NULL
nitrocellulose	NULL
membrane	NULL
(	NULL
Amersham	NULL
,	NULL
Arlington	NULL
Heights	NULL
,	NULL
IL	NULL
)	NULL
.	NULL

After	NULL
blocking	NULL
with	NULL
10	NULL
%	NULL
dry	NULL
milk	NULL
in	NULL
1	NULL
%	NULL
X	NULL
PBS/0.1	NULL
%	NULL
Tween	NULL
20	NULL
,	NULL
membranes	NULL
were	NULL
then	NULL
incubated	NULL
with	NULL
anti-PPAR-y	NULL
(	NULL
1/2000	NULL
diluted	NULL
in	NULL
PBST	NULL
)	NULL
for	NULL
2	NULL
h	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

They	NULL
were	NULL
then	NULL
briefly	NULL
washed	NULL
and	NULL
incubated	NULL
with	NULL
a	NULL
goat	NULL
anti-rabbit-HRP	NULL
conjugate	NULL
(	NULL
1/3000	NULL
diluted	NULL
in	NULL
10	NULL
%	NULL
milk-PBST	NULL
)	NULL
for	NULL
1	NULL
h.	NULL
Bands	NULL
were	NULL
visualized	NULL
with	NULL
ECL	NULL
according	NULL
to	NULL
the	NULL
manufacturer	NULL
's	NULL
instructions	NULL
(	NULL
Amersham	NULL
)	NULL
.	NULL

The	NULL
density	NULL
of	NULL
the	NULL
resulting	NULL
bends	NULL
was	NULL
analyzed	NULL
with	NULL
Kodak	NULL
Digital	NULL
Science	NULL
software	NULL
(	NULL
New	NULL
Heaven	NULL
,	NULL
CT	NULL
)	NULL
.	NULL

Isolation	NULL
of	NULL
normal	NULL
mouse	NULL
B	NULL
lymphocytes	NULL
Mouse	NULL
B	NULL
lymphocytes	NULL
were	NULL
isolated	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
20	NULL
)	NULL
.	NULL

In	NULL
brief	NULL
,	NULL
normal	NULL
mouse	NULL
splenic	NULL
B	NULL
lymphocytes	NULL
were	NULL
isolated	NULL
from	NULL
7-	NULL
to	NULL
22-wk-old	NULL
C57BL/6JXDBA/2J	NULL
(	NULL
B6D2	NULL
(	NULL
F	NULL
;	NULL
)	NULL
)	NULL
male	NULL
mice	NULL
(	NULL
The	NULL
Jackson	NULL
Laboratory	NULL
,	NULL
Bar	NULL
Harbor	NULL
,	NULL
ME	NULL
)	NULL
.	NULL

Erythrocytes	NULL
were	NULL
lysed	NULL
with	NULL
ammonium	NULL
chloride	NULL
buffer	NULL
,	NULL
and	NULL
the	NULL
suspension	NULL
was	NULL
depleted	NULL
of	NULL
adherent	NULL
cells	NULL
by	NULL
two	NULL
successive	NULL
rounds	NULL
of	NULL
adherence	NULL
on	NULL
Falcon	NULL
tissue	NULL
culture	NULL
dishes	NULL
(	NULL
Becton	NULL
Dickinson	NULL
,	NULL
Lincoln	NULL
Park	NULL
,	NULL
NJ	NULL
)	NULL
at	NULL
37°C	NULL
for	NULL
2	NULL
h.	NULL
Nonadherent	NULL
cells	NULL
were	NULL
collected	NULL
by	NULL
rinsing	NULL
the	NULL
plates	NULL
with	NULL
warm	NULL
medium	NULL
.	NULL

T	NULL
cells	NULL
were	NULL
depleted	NULL
with	NULL
anti-T	NULL
cell	NULL
cocktail	NULL
consisting	NULL
of	NULL
Abs	NULL
30-H12	NULL
(	NULL
anti-Thy	NULL
1.2	NULL
)	NULL
,	NULL
3.155	NULL
(	NULL
anti-CD8	NULL
)	NULL
,	NULL
and	NULL
GK	NULL
1.5	NULL
(	NULL
anti-CD4	NULL
)	NULL
and	NULL
low	NULL
toxicity	NULL
baby	NULL
rabbit	NULL
complement	NULL
(	NULL
Cedarlane	NULL
,	NULL
Hornby	NULL
,	NULL
Canada	NULL
)	NULL
followed	NULL
by	NULL
incubation	NULL
at	NULL
37°C	NULL
.	NULL

The	NULL
cells	NULL
were	NULL
washed	NULL
and	NULL
PPAR-y	NULL
ON	NULL
B-LINEAGE	NULL
CELLS	NULL
counted	NULL
,	NULL
and	NULL
viability	NULL
was	NULL
determined	NULL
using	NULL
the	NULL
trypan	NULL
blue	NULL
exclusion	NULL
method	NULL
.	NULL

B	NULL
lymphocytes	NULL
isolated	NULL
in	NULL
this	NULL
manner	NULL
are	NULL
>	NULL
95	NULL
%	NULL
surface	NULL
IgM	NULL
positive	NULL
,	NULL
are	NULL
Thy-1.2	NULL
negative	NULL
(	NULL
as	NULL
measured	NULL
by	NULL
indirect	NULL
immunofluorescence	NULL
and	NULL
flow	NULL
cytometry	NULL
)	NULL
,	NULL
and	NULL
do	NULL
not	NULL
express	NULL
esterase	NULL
(	NULL
a-naphthyl	NULL
acetate	NULL
method	NULL
)	NULL
or	NULL
phagocytic	NULL
activity	NULL
(	NULL
latex	NULL
bead	NULL
method	NULL
)	NULL
.	NULL

Purification	NULL
of	NULL
small	NULL
,	NULL
dense	NULL
,	NULL
resting	NULL
B	NULL
lymphocytes	NULL
B	NULL
cells	NULL
were	NULL
separated	NULL
based	NULL
on	NULL
the	NULL
method	NULL
of	NULL
using	NULL
a	NULL
discontinuous	NULL
Per-coll	NULL
gradient	NULL
(	NULL
Pharmacia	NULL
,	NULL
Piscataway	NULL
,	NULL
NJ	NULL
)	NULL
(	NULL
21	NULL
)	NULL
that	NULL
was	NULL
modified	NULL
to	NULL
isolate	NULL
the	NULL
smallest	NULL
,	NULL
densest	NULL
cells	NULL
(	NULL
20	NULL
)	NULL
.	NULL

Cells	NULL
resuspended	NULL
in	NULL
PBS	NULL
(	NULL
1	NULL
X	NULL
10°	NULL
)	NULL
were	NULL
applied	NULL
to	NULL
the	NULL
gradient	NULL
and	NULL
centrifuged	NULL
for	NULL
12	NULL
min	NULL
at	NULL
3000	NULL
rpm	NULL
.	NULL

Cells	NULL
from	NULL
the	NULL
lowest	NULL
interface	NULL
(	NULL
resting	NULL
B	NULL
lymphocytes	NULL
)	NULL
were	NULL
harvested	NULL
.	NULL

This	NULL
procedure	NULL
yields	NULL
30-50	NULL
%	NULL
of	NULL
the	NULL
starting	NULL
population	NULL
.	NULL

Small	NULL
,	NULL
dense	NULL
,	NULL
resting	NULL
B	NULL
lymphocytes	NULL
fractionated	NULL
by	NULL
this	NULL
method	NULL
are	NULL
>	NULL
98	NULL
%	NULL
surface	NULL
IgM	NULL
*	NULL
(	NULL
as	NULL
measured	NULL
by	NULL
indirect	NULL
immunofluorescence	NULL
and	NULL
flow	NULL
cytometry	NULL
)	NULL
.	NULL

The	NULL
median	NULL
volume	NULL
of	NULL
cells	NULL
in	NULL
the	NULL
lower	NULL
fraction	NULL
was	NULL
105-115	NULL
fi	NULL
as	NULL
determined	NULL
by	NULL
analysis	NULL
on	NULL
a	NULL
Coulter	NULL
Channelyzer	NULL
256	NULL
(	NULL
Coulter	NULL
Electronics	NULL
,	NULL
Hialeah	NULL
,	NULL
FL	NULL
)	NULL
(	NULL
22	NULL
)	NULL
.	NULL

Viability	NULL
assays	NULL
Small	NULL
,	NULL
resting	NULL
B	NULL
lymphocytes	NULL
and	NULL
B	NULL
lymphomas	NULL
were	NULL
cultured	NULL
in	NULL
flat-bottom	NULL
96-well	NULL
microtiter	NULL
plates	NULL
(	NULL
Falcon	NULL
,	NULL
Becton	NULL
Dickinson	NULL
)	NULL
.	NULL

Cells	NULL
were	NULL
incubated	NULL
in	NULL
triplicate	NULL
at	NULL
5	NULL
X	NULL
10°	NULL
cell/ml	NULL
with	NULL
15d-PGJ	NULL
;	NULL
,	NULL
,	NULL
PGF	NULL
;	NULL
,	NULL
,	NULL
,	NULL
or	NULL
DMSO	NULL
as	NULL
a	NULL
control	NULL
at	NULL
doses	NULL
of	NULL
0.001-1000	NULL
uM	NULL
for	NULL
48	NULL
h.	NULL
Then	NULL
a	NULL
solution	NULL
of	NULL
5	NULL
mg/ml	NULL
of	NULL
MTT	NULL
in	NULL
1X	NULL
PBS	NULL
was	NULL
added	NULL
(	NULL
10	NULL
wl/well	NULL
)	NULL
.	NULL

After	NULL
4	NULL
h	NULL
at	NULL
37°C	NULL
the	NULL
plate	NULL
was	NULL
centrifuged	NULL
,	NULL
the	NULL
medium	NULL
was	NULL
removed	NULL
,	NULL
and	NULL
the	NULL
insoluble	NULL
precipitate	NULL
was	NULL
dissolved	NULL
by	NULL
adding	NULL
200	NULL
ul	NULL
of	NULL
DMSO	NULL
to	NULL
each	NULL
well	NULL
.	NULL

The	NULL
plate	NULL
was	NULL
read	NULL
at	NULL
570	NULL
nm	NULL
on	NULL
the	NULL
ELISA	NULL
reader	NULL
(	NULL
Dynatech	NULL
,	NULL
Chantilly	NULL
,	NULL
VA	NULL
)	NULL
.	NULL

Proliferation	NULL
assays	NULL
An	NULL
experimental	NULL
set-up	NULL
similar	NULL
to	NULL
that	NULL
described	NULL
above	NULL
for	NULL
the	NULL
viability	NULL
assays	NULL
was	NULL
used	NULL
to	NULL
assess	NULL
proliferation	NULL
.	NULL

After	NULL
the	NULL
initial	NULL
24	NULL
h	NULL
of	NULL
a	NULL
48-h	NULL
incubation	NULL
period	NULL
,	NULL
cells	NULL
were	NULL
pulsed	NULL
with	NULL
1	NULL
uCi/well	NULL
of	NULL
[	NULL
°HJthymidine	NULL
.	NULL

Plates	NULL
were	NULL
harvested	NULL
with	NULL
a	NULL
Micromate	NULL
196	NULL
cell	NULL
harvester	NULL
(	NULL
Packard	NULL
,	NULL
Me-riden	NULL
CT	NULL
)	NULL
,	NULL
and	NULL
incorporation	NULL
of	NULL
[	NULL
°H	NULL
]	NULL
thymidine	NULL
was	NULL
determined	NULL
with	NULL
a	NULL
Matrix	NULL
96	NULL
direct	NULL
beta	NULL
counter	NULL
(	NULL
Packard	NULL
)	NULL
.	NULL

Annexin	NULL
V-fluorescein	NULL
Double	NULL
staining	NULL
for	NULL
annexin	NULL
V-FITC	NULL
binding	NULL
and	NULL
for	NULL
cellular	NULL
DNA	NULL
using	NULL
PI	NULL
was	NULL
performed	NULL
as	NULL
follows	NULL
.	NULL

Cells	NULL
(	NULL
1	NULL
X	NULL
10°/ml	NULL
)	NULL
were	NULL
incubated	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
the	NULL
absence	NULL
of	NULL
PPAR-y	NULL
agonists	NULL
,	NULL
irrelevant	NULL
agonists	NULL
,	NULL
medium	NULL
only	NULL
,	NULL
or	NULL
DMSO	NULL
in	NULL
flat-bottom	NULL
plates	NULL
(	NULL
Falcon	NULL
)	NULL
for	NULL
2-6	NULL
h	NULL
,	NULL
then	NULL
washed	NULL
twice	NULL
in	NULL
cold	NULL
PBS	NULL
.	NULL

The	NULL
pellet	NULL
was	NULL
resuspended	NULL
in	NULL
cold	NULL
binding	NULL
buffer	NULL
(	NULL
10	NULL
mM	NULL
HEPES	NULL
(	NULL
pH	NULL
7.4	NULL
)	NULL
,	NULL
140	NULL
mM	NULL
NaCl	NULL
,	NULL
2.5	NULL
mM	NULL
CaCl	NULL
,	NULL
,	NULL
and	NULL
0.1	NULL
%	NULL
BSA	NULL
)	NULL
to	NULL
a	NULL
concentration	NULL
of	NULL
1	NULL
X	NULL
10°	NULL
cells/ml	NULL
.	NULL

In	NULL
a	NULL
separate	NULL
tube	NULL
,	NULL
100	NULL
pl	NULL
of	NULL
the	NULL
cell	NULL
suspension	NULL
was	NULL
incubated	NULL
for	NULL
15	NULL
min	NULL
with	NULL
10	NULL
wl	NULL
of	NULL
annexin	NULL
V-FITC	NULL
.	NULL

Samples	NULL
were	NULL
placed	NULL
on	NULL
ice	NULL
and	NULL
protected	NULL
from	NULL
light	NULL
.	NULL

Without	NULL
washing	NULL
,	NULL
380	NULL
ul	NULL
of	NULL
cold	NULL
1	NULL
%	NULL
binding	NULL
buffer	NULL
was	NULL
added	NULL
to	NULL
each	NULL
tube	NULL
.	NULL

Then	NULL
,	NULL
to	NULL
each	NULL
sample	NULL
100	NULL
ul	NULL
of	NULL
PI	NULL
(	NULL
0.5	NULL
mg/ml	NULL
)	NULL
was	NULL
added	NULL
before	NULL
the	NULL
samples	NULL
were	NULL
analyzed	NULL
by	NULL
flow	NULL
cytometry	NULL
.	NULL

All	NULL
samples	NULL
were	NULL
analyzed	NULL
on	NULL
an	NULL
Beckman	NULL
Coulter	NULL
EPICS	NULL
Elite	NULL
ESP	NULL
flow	NULL
cytometer	NULL
(	NULL
Beckman	NULL
Coulter	NULL
,	NULL
Hialeah	NULL
,	NULL
FL	NULL
)	NULL
with	NULL
a	NULL
488-nm	NULL
argon	NULL
laser	NULL
.	NULL

FITC	NULL
was	NULL
collected	NULL
through	NULL
a	NULL
525-nm	NULL
bandpass	NULL
filter	NULL
,	NULL
and	NULL
PI	NULL
was	NULL
collected	NULL
through	NULL
610-nm	NULL
bandpass	NULL
filters	NULL
.	NULL

Analyses	NULL
were	NULL
performed	NULL
with	NULL
EPICS	NULL
Elite	NULL
software	NULL
.	NULL

TUNEL	NULL
assay	NULL
The	NULL
TUNEL	NULL
acronym	NULL
stands	NULL
for	NULL
terminal	NULL
deoxynucleotidyl	NULL
transferase-mediated	NULL
dUTP-biotin	NULL
nick	NULL
end	NULL
labeling	NULL
of	NULL
DNA	NULL
fragmentation	NULL
sites	NULL
(	NULL
23	NULL
)	NULL
.	NULL

To	NULL
study	NULL
apoptosis	NULL
by	NULL
the	NULL
TUNEL	NULL
assay	NULL
,	NULL
5.0	NULL
X	NULL
10°	NULL
cells/ml	NULL
were	NULL
incubated	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
the	NULL
absence	NULL
of	NULL
PPAR-y	NULL
agonists	NULL
and	NULL
nonagonists	NULL
or	NULL
in	NULL
medium	NULL
only	NULL
and	NULL
DMSO	NULL
as	NULL
controls	NULL
in	NULL
flat-bottom	NULL
plates	NULL
(	NULL
Falcon	NULL
)	NULL
for	NULL
6-12	NULL
h.	NULL
Cells	NULL
were	NULL
then	NULL
washed	NULL
twice	NULL
in	NULL
1X	NULL
PBS	NULL
,	NULL
air-dried	NULL
on	NULL
glass	NULL
microscope	NULL
slides	NULL
(	NULL
VWR	NULL
,	NULL
Media	NULL
,	NULL
PA	NULL
)	NULL
,	NULL
and	NULL
fixed	NULL
in	NULL
4	NULL
%	NULL
paraformaldehyde-0.5	NULL
%	NULL
Tween	NULL
for	NULL
10-15	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

Next	NULL
,	NULL
the	NULL
endogenous	NULL
peroxidase	NULL
activity	NULL
was	NULL
quenched	NULL
for	NULL
15	NULL
min	NULL
.	NULL

To	NULL
label	NULL
cells	NULL
,	NULL
a	NULL
solution	NULL
containing	NULL
recombinant	NULL
terminal	NULL
deoxynucleotidyl	NULL
transferase	NULL
(	NULL
Life	NULL
Technologies	NULL
,	NULL
Grand	NULL
Island	NULL
,	NULL
NY	NULL
)	NULL
,	NULL
biotin	NULL
dUTP	NULL
(	NULL
Roche	NULL
,	NULL
Indianapolis	NULL
,	NULL
IN	NULL
)	NULL
,	NULL
and	NULL
5	NULL
%	NULL
terminal	NULL
deoxynucleotidyl	NULL
transferase	NULL
buffer	NULL
(	NULL
Life	NULL
Technologies	NULL
)	NULL
was	NULL
applied	NULL
to	NULL
experimental	NULL
samples	NULL
for	NULL
1	NULL
h	NULL
at	NULL
37°C	NULL
.	NULL

The	NULL
TUNEL	NULL
reaction	NULL
was	NULL
finished	NULL
with	NULL
termination	NULL
buffer	NULL
(	NULL
300	NULL
mM	NULL
NaCl	NULL
and	NULL
30	NULL
mM	NULL
sodium	NULL
citrate	NULL
)	NULL
followed	NULL
by	NULL
water	NULL
rinses	NULL
.	NULL

Samples	NULL
were	NULL
blocked	NULL
with	NULL
2	NULL
%	NULL
BSA	NULL
for	NULL
10	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
and	NULL
treated	NULL
with	NULL
streptavidin	NULL
peroxidase	NULL
(	NULL
1/6000	NULL
;	NULL
Zymed	NULL
,	NULL
South	NULL
San	NULL
Francisco	NULL
,	NULL
CA	NULL
)	NULL
for	NULL
30	NULL
min	NULL
followed	NULL
by	NULL
aminoethylcear-bazole	NULL
substrate	NULL
(	NULL
Zymed	NULL
)	NULL
for	NULL
15	NULL
min	NULL
,	NULL
coverslipped	NULL
with	NULL
Immuno-Mount	NULL
(	NULL
Shandon	NULL
,	NULL
Pittsburgh	NULL
,	NULL
PA	NULL
)	NULL
,	NULL
and	NULL
photographed	NULL
with	NULL
an	NULL
Olympus	NULL
BMAX	NULL
B201	NULL
microscope	NULL
(	NULL
New	NULL
Hyde	NULL
Park	NULL
,	NULL
NY	NULL
)	NULL
.	NULL

6107	NULL
'01	NULL
Aepy	NULL
uo	NULL
isan	NULL
$	NULL
4q	NULL
310	NULL
founwurrf'mmm//	NULL
:	NULL
dyy	NULL
wo	NULL
papeojumoG	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
Immunoprecipitation	NULL
and	NULL
Western	NULL
blot	NULL
analysis	NULL
of	NULL
phosphorylated	NULL
mitogen-activated	NULL
protein	NULL
kinase	NULL
(	NULL
MAPK	NULL
)	NULL
Nuclear	NULL
protein	NULL
extracts	NULL
from	NULL
B	NULL
cells	NULL
were	NULL
prepared	NULL
as	NULL
previously	NULL
described	NULL
(	NULL
24	NULL
)	NULL
and	NULL
immunoprecipitated	NULL
overnight	NULL
using	NULL
a	NULL
polyclonal	NULL
anti-phosphotyrosine	NULL
Ab	NULL
(	NULL
Transduction	NULL
Laboratories	NULL
,	NULL
Lexington	NULL
,	NULL
KY	NULL
)	NULL
.	NULL

Protein	NULL
A-agarose	NULL
was	NULL
added	NULL
,	NULL
and	NULL
samples	NULL
were	NULL
incubated	NULL
for	NULL
1	NULL
h	NULL
at	NULL
4°C	NULL
.	NULL

Complexes	NULL
were	NULL
washed	NULL
with	NULL
hypotonic	NULL
buffer	NULL
containing	NULL
0.2	NULL
%	NULL
Nonidet	NULL
P-40	NULL
,	NULL
and	NULL
immunoprecipitated	NULL
proteins	NULL
were	NULL
separated	NULL
by	NULL
discontinuous	NULL
9	NULL
%	NULL
PAGE	NULL
and	NULL
transferred	NULL
to	NULL
Immobilon	NULL
membranes	NULL
(	NULL
Millipore	NULL
,	NULL
Bedford	NULL
,	NULL
MA	NULL
)	NULL
.	NULL

After	NULL
blocking	NULL
with	NULL
5	NULL
%	NULL
powdered	NULL
milk	NULL
in	NULL
Tris-buffered	NULL
saline	NULL
containing	NULL
1	NULL
%	NULL
Tween	NULL
,	NULL
membranes	NULL
were	NULL
incubated	NULL
with	NULL
1/1000	NULL
monoclonal	NULL
anti-MAPK	NULL
Ab	NULL
(	NULL
anti-ERK2	NULL
,	NULL
Upstate	NULL
Biotechnology	NULL
,	NULL
Lake	NULL
Placid	NULL
,	NULL
NY	NULL
)	NULL
overnight	NULL
at	NULL
room	NULL
temperature	NULL
and	NULL
washed	NULL
,	NULL
and	NULL
the	NULL
secondary	NULL
,	NULL
rabbit	NULL
anti-mouse	NULL
IgG	NULL
was	NULL
added	NULL
at	NULL
1/1000	NULL
.	NULL

The	NULL
signals	NULL
were	NULL
visualized	NULL
using	NULL
an	NULL
ECL	NULL
detection	NULL
kit	NULL
.	NULL

Results	NULL
B-lineage	NULL
cells	NULL
express	NULL
PPAR-y	NULL
mRNA	NULL
and	NULL
protein	NULL
15d-PGJ	NULL
;	NULL
,	NULL
,	NULL
in	NULL
contrast	NULL
to	NULL
other	NULL
PGs	NULL
,	NULL
is	NULL
actively	NULL
incorporated	NULL
into	NULL
the	NULL
cell	NULL
by	NULL
unknown	NULL
mechanisms	NULL
and	NULL
transferred	NULL
into	NULL
the	NULL
nucleus	NULL
,	NULL
where	NULL
it	NULL
binds	NULL
to	NULL
PPAR-y	NULL
(	NULL
9	NULL
)	NULL
.	NULL

To	NULL
assess	NULL
whether	NULL
small	NULL
,	NULL
dense	NULL
,	NULL
resting	NULL
B	NULL
lymphocytes	NULL
and	NULL
B	NULL
lymphoma	NULL
cells	NULL
express	NULL
mRNA	NULL
for	NULL
PPAR-y	NULL
,	NULL
RT-PCR	NULL
analysis	NULL
was	NULL
used	NULL
.	NULL

The	NULL
B	NULL
lymphoma	NULL
cells	NULL
analyzed	NULL
ranged	NULL
from	NULL
70Z/3	NULL
(	NULL
pre-B	NULL
cell	NULL
)	NULL
to	NULL
J558	NULL
(	NULL
a	NULL
plasmacytoma	NULL
)	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
normal	NULL
splenic	NULL
B	NULL
cells	NULL
and	NULL
all	NULL
B	NULL
lymphoma	NULL
cells	NULL
tested	NULL
yielded	NULL
a	NULL
250-bp	NULL
product	NULL
characteristic	NULL
of	NULL
PPAR-y	NULL
mRNA	NULL
.	NULL

C3H10T1/2	NULL
cells	NULL
,	NULL
a	NULL
fibroblast-like	NULL
line	NULL
,	NULL
was	NULL
used	NULL
as	NULL
a	NULL
positive	NULL
control	NULL
for	NULL
PPAR-y	NULL
mRNA	NULL
(	NULL
9	NULL
)	NULL
.	NULL

Normal	NULL
B	NULL
cells	NULL
and	NULL
the	NULL
same	NULL
panel	NULL
of	NULL
B	NULL
lymphoma	NULL
cells	NULL
as	NULL
that	NULL
used	NULL
for	NULL
RT-PCR	NULL
analysis	NULL
were	NULL
lysed	NULL
and	NULL
analyzed	NULL
for	NULL
PPAR-y	NULL
protein	NULL
by	NULL
Western	NULL
blot	NULL
using	NULL
a	NULL
polyclonal	NULL
Ab	NULL
.	NULL

PPAR-y	NULL
appeared	NULL
as	NULL
a	NULL
single	NULL
band	NULL
with	NULL
a	NULL
characteristic	NULL
molecular	NULL
mass	NULL
of	NULL
67	NULL
kDa	NULL
on	NULL
all	NULL
the	NULL
B-lineage	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

2A	NULL
)	NULL
.	NULL

While	NULL
each	NULL
cell	NULL
type	NULL
expressed	NULL
mRNA	NULL
for	NULL
PPAR-y	NULL
,	NULL
the	NULL
relative	NULL
amount	NULL
of	NULL
PPAR-y	NULL
protein	NULL
did	NULL
not	NULL
vary	NULL
significantly	NULL
in	NULL
B	NULL
lymphoma	NULL
cells	NULL
at	NULL
different	NULL
stages	NULL
of	NULL
differentiation	NULL
,	NULL
as	NULL
shown	NULL
by	NULL
the	NULL
Western	NULL
blot	NULL
(	NULL
Fig	NULL
.	NULL

2B	NULL
)	NULL
.	NULL

Normal	NULL
splenic	NULL
B	NULL
cells	NULL
,	NULL
however	NULL
,	NULL
did	NULL
express	NULL
a	NULL
relatively	NULL
larger	NULL
amount	NULL
of	NULL
PPAR-y	NULL
protein	NULL
.	NULL

15d-PGJ	NULL
;	NULL
,	NULL
has	NULL
a	NULL
cytotoxic	NULL
effect	NULL
on	NULL
mouse	NULL
B-lineage	NULL
cells	NULL
15d-PGJ	NULL
;	NULL
,	NULL
is	NULL
the	NULL
only	NULL
physiological	NULL
ligand	NULL
,	NULL
known	NULL
to	NULL
date	NULL
to	NULL
bind	NULL
PPAR-y	NULL
(	NULL
9	NULL
,	NULL
25	NULL
)	NULL
.	NULL

[	NULL
°H	NULL
]	NULL
thymidine	NULL
incorporation	NULL
assays	NULL
were	NULL
used	NULL
to	NULL
determine	NULL
whether	NULL
15d-PGJ	NULL
;	NULL
,	NULL
had	NULL
an	NULL
effect	NULL
on	NULL
proliferation	NULL
of	NULL
B-lineage	NULL
cells	NULL
.	NULL

15d-PGJ	NULL
;	NULL
,	NULL
was	NULL
used	NULL
from	NULL
0.001-10	NULL
uM	NULL
for	NULL
48	NULL
h	NULL
,	NULL
and	NULL
PGF	NULL
;	NULL
,	NULL
,	NULL
was	NULL
included	NULL
as	NULL
a	NULL
negative	NULL
control	NULL
prostanoid	NULL
.	NULL

Murine	NULL
B	NULL
lymphoma	NULL
cell	NULL
lines	NULL
representative	NULL
of	NULL
different	NULL
stages	NULL
of	NULL
B	NULL
cell	NULL
ontogeny	NULL
were	NULL
used	NULL
as	NULL
well	NULL
as	NULL
small	NULL
,	NULL
dense	NULL
,	NULL
resting	NULL
mouse	NULL
B	NULL
cells	NULL
.	NULL

Fig	NULL
.	NULL

3	NULL
reveals	NULL
the	NULL
antiproliferative	NULL
effect	NULL
that	NULL
15d-PGJ	NULL
;	NULL
,	NULL
had	NULL
on	NULL
B	NULL
cell	NULL
lines	NULL
at	NULL
1	NULL
wM	NULL
.	NULL

15d-PGJ	NULL
,	NULL
inhibited	NULL
[	NULL
°H	NULL
]	NULL
thymidine	NULL
incorporation	NULL
in	NULL
the	NULL
different	NULL
B	NULL
cell	NULL
lines	NULL
regardless	NULL
of	NULL
their	NULL
stage	NULL
of	NULL
devel-opment	NULL
.	NULL

Normal	NULL
B	NULL
lymphocytes	NULL
and	NULL
lymphoma	NULL
cells	NULL
were	NULL
homo-	NULL
8	NULL
so	NULL
x	NULL
&	NULL
i	NULL
a	NULL
§	NULL
f	NULL
t	NULL
L	NULL
€	NULL
©	NULL
33	NULL
T	NULL
_	NULL
c	NULL
r	NULL
8	NULL
§	NULL
RP	NULL
$	NULL
a	NULL
i	NULL
&	NULL
$	NULL
f	NULL
r	NULL
m	NULL
m	NULL
(	NULL
8	NULL
u-	NULL
z	NULL
o	NULL
>	NULL
o	NULL
FIGURE	NULL
1	NULL
.	NULL

B-lineage	NULL
cells	NULL
express	NULL
mRNA	NULL
for	NULL
PPAR-y	NULL
.	NULL

Two	NULL
micrograms	NULL
of	NULL
RNA	NULL
was	NULL
reversed	NULL
transcribed	NULL
using	NULL
Moloney	NULL
murine	NULL
leukemia	NULL
virus	NULL
reverse	NULL
transcriptase	NULL
and	NULL
random	NULL
hexamers	NULL
(	NULL
see	NULL
Materials	NULL
and	NULL
Methods	NULL
)	NULL
.	NULL

PCR	NULL
reactions	NULL
for	NULL
mouse	NULL
PPAR-y	NULL
were	NULL
completed	NULL
using	NULL
Taq	NULL
DNA	NULL
polymerase	NULL
and	NULL
mouse	NULL
PPAR-y	NULL
primers	NULL
.	NULL

The	NULL
expected	NULL
product	NULL
was	NULL
250	NULL
bp	NULL
.	NULL

The	NULL
identities	NULL
of	NULL
these	NULL
products	NULL
were	NULL
confirmed	NULL
by	NULL
sequencing	NULL
.	NULL

No	NULL
products	NULL
were	NULL
observed	NULL
in	NULL
samples	NULL
without	NULL
reverse	NULL
transcriptase	NULL
.	NULL

6943	NULL
geneous	NULL
in	NULL
their	NULL
sensitivity	NULL
to	NULL
the	NULL
antiproliferative	NULL
effect	NULL
caused	NULL
by	NULL
15d-PGJ	NULL
;	NULL
,	NULL
at	NULL
1	NULL
uM	NULL
.	NULL

The	NULL
incorporation	NULL
of	NULL
was	NULL
not	NULL
inhibited	NULL
by	NULL
the	NULL
presence	NULL
of	NULL
PGF	NULL
,	NULL
,	NULL
,	NULL
.	NULL

C3H10T1/2	NULL
were	NULL
not	NULL
inhibited	NULL
in	NULL
their	NULL
[	NULL
°H	NULL
]	NULL
thymidine	NULL
incorporation	NULL
by	NULL
either	NULL
15d-PGJ	NULL
,	NULL
or	NULL
PGF	NULL
;	NULL
,	NULL
,	NULL
at	NULL
1	NULL
uM	NULL
.	NULL

To	NULL
determine	NULL
whether	NULL
the	NULL
antiproliferative	NULL
effect	NULL
that	NULL
15d-PGJ	NULL
,	NULL
has	NULL
on	NULL
B-lineage	NULL
cells	NULL
is	NULL
cytotoxic	NULL
,	NULL
MTT	NULL
assays	NULL
were	NULL
performed	NULL
.	NULL

The	NULL
MTT	NULL
assay	NULL
evaluates	NULL
cell	NULL
viability	NULL
via	NULL
cleavage	NULL
of	NULL
MTT	NULL
into	NULL
a	NULL
dark	NULL
blue	NULL
crystalline	NULL
compound	NULL
by	NULL
mitochondrial	NULL
suc-cinic	NULL
dehydrogenases	NULL
active	NULL
only	NULL
in	NULL
living	NULL
cells	NULL
.	NULL

Fig	NULL
.	NULL

4	NULL
depicts	NULL
the	NULL
effects	NULL
of	NULL
15d-PGJ	NULL
,	NULL
on	NULL
the	NULL
viability	NULL
of	NULL
the	NULL
different	NULL
B	NULL
cell	NULL
lines	NULL
.	NULL

Once	NULL
again	NULL
15d-PGJ	NULL
;	NULL
,	NULL
had	NULL
a	NULL
uniformly	NULL
negative	NULL
effect	NULL
on	NULL
B-lineage	NULL
cells	NULL
regardless	NULL
of	NULL
the	NULL
stage	NULL
of	NULL
B	NULL
cell	NULL
ontogeny	NULL
.	NULL

Therefore	NULL
,	NULL
15d-PGJ	NULL
,	NULL
is	NULL
a	NULL
negative	NULL
regulator	NULL
of	NULL
B-lineage	NULL
cells	NULL
.	NULL

The	NULL
mechanism	NULL
of	NULL
15d-PGJ	NULL
;	NULL
cytotoxicity	NULL
on	NULL
B-lineage	NULL
cells	NULL
involves	NULL
PPAR-y	NULL
To	NULL
investigate	NULL
whether	NULL
15d-PGJ	NULL
;	NULL
,	NULL
involves	NULL
PPAR-y	NULL
as	NULL
the	NULL
mechanism	NULL
for	NULL
the	NULL
cytotoxic	NULL
effect	NULL
,	NULL
we	NULL
used	NULL
additional	NULL
known	NULL
PPAR	NULL
activators	NULL
.	NULL

Troglitazone	NULL
and	NULL
ciglitazone	NULL
are	NULL
both	NULL
antihyperglyce-mic	NULL
agents	NULL
that	NULL
are	NULL
PPAR-y-selective	NULL
activators	NULL
(	NULL
9	NULL
,	NULL
26	NULL
)	NULL
.	NULL

WY14,643	NULL
is	NULL
a	NULL
fibrate	NULL
hypolipidemic	NULL
drug	NULL
that	NULL
activates	NULL
PPARa	NULL
selectively	NULL
(	NULL
27	NULL
)	NULL
,	NULL
and	NULL
eicosatetraynoic	NULL
acid	NULL
is	NULL
a	NULL
synthetic	NULL
arachidonic	NULL
acid	NULL
analogue	NULL
that	NULL
binds	NULL
PPAR-a	NULL
«	NULL
selectively	NULL
(	NULL
28	NULL
)	NULL
.	NULL

PGF	NULL
,	NULL
is	NULL
used	NULL
as	NULL
a	NULL
negative	NULL
control	NULL
prostanoid	NULL
,	NULL
because	NULL
it	NULL
does	NULL
not	NULL
bind	NULL
to	NULL
PPARs	NULL
(	NULL
9	NULL
,	NULL
25	NULL
)	NULL
.	NULL

[	NULL
*HIJthymidine	NULL
incorporation	NULL
assays	NULL
were	NULL
per-formed	NULL
,	NULL
and	NULL
representative	NULL
data	NULL
using	NULL
CH31	NULL
cells	NULL
are	NULL
depicted	NULL
in	NULL
Fig	NULL
.	NULL

5	NULL
.	NULL

15d-PGJ	NULL
,	NULL
inhibited	NULL
the	NULL
incorporation	NULL
of	NULL
[	NULL
°H	NULL
]	NULL
thymidine	NULL
in	NULL
a	NULL
dose-dependent	NULL
manner	NULL
,	NULL
with	NULL
total	NULL
inhibition	NULL
at	NULL
1	NULL
wM	NULL
.	NULL

The	NULL
PPAR-y-selective	NULL
agonists	NULL
ciglitazone	NULL
and	NULL
troglitazone	NULL
mimicked	NULL
the	NULL
effect	NULL
of	NULL
15d-PGJ	NULL
;	NULL
,	NULL
on	NULL
the	NULL
inhibition	NULL
of	NULL
[	NULL
°H	NULL
]	NULL
thymidine	NULL
incorporation	NULL
.	NULL

Troglitazone	NULL
and	NULL
ciglitazone	NULL
were	NULL
10-fold	NULL
less	NULL
potent	NULL
than	NULL
15d-PGJ	NULL
;	NULL
,	NULL
in	NULL
their	NULL
antiproliferative	NULL
effect	NULL
.	NULL

This	NULL
is	NULL
similar	NULL
to	NULL
the	NULL
increased	NULL
ability	NULL
of	NULL
15d-PGJ	NULL
,	NULL
compared	NULL
with	NULL
ciglitazone	NULL
and	NULL
troglitazone	NULL
to	NULL
bind	NULL
PPAR-y	NULL
(	NULL
11	NULL
,	NULL
26	NULL
)	NULL
.	NULL

Non-PPAR-y	NULL
agonists	NULL
such	NULL
as	NULL
PGF	NULL
;	NULL
,	NULL
,	NULL
,	NULL
WY14,643	NULL
,	NULL
and	NULL
eicosatetraynoic	NULL
acid	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
failed	NULL
to	NULL
inhibit	NULL
the	NULL
proliferation	NULL
of	NULL
CH31	NULL
cells	NULL
.	NULL

These	NULL
data	NULL
indicate	NULL
that	NULL
the	NULL
mechanism	NULL
by	NULL
which	NULL
15d-PGJ	NULL
;	NULL
,	NULL
interacts	NULL
with	NULL
B-lineage	NULL
cells	NULL
involves	NULL
in	NULL
part	NULL
PPAR-y	NULL
.	NULL

These	NULL
experiments	NULL
were	NULL
repeated	NULL
with	NULL
other	NULL
B	NULL
lymphomas	NULL
,	NULL
such	NULL
as	NULL
70Z/3	NULL
,	NULL
CH12	NULL
,	NULL
and	NULL
ECH4O08.1	NULL
,	NULL
with	NULL
similar	NULL
results	NULL
.	NULL

15d-PGJ	NULL
;	NULL
induces	NULL
apoptosis	NULL
in	NULL
B-lineage	NULL
cells	NULL
Death	NULL
by	NULL
apoptosis	NULL
is	NULL
characterized	NULL
by	NULL
key	NULL
morphological	NULL
features	NULL
.	NULL

These	NULL
include	NULL
changes	NULL
in	NULL
the	NULL
plasma	NULL
membrane	NULL
,	NULL
such	NULL
as	NULL
loss	NULL
of	NULL
membrane	NULL
asymmetry	NULL
and	NULL
attachment	NULL
,	NULL
condensation	NULL
of	NULL
the	NULL
cytoplasm	NULL
and	NULL
nucleus	NULL
,	NULL
and	NULL
internucleosomal	NULL
cleavage	NULL
of	NULL
DNA	NULL
by	NULL
an	NULL
endogenous	NULL
endonuclease	NULL
.	NULL

In	NULL
the	NULL
final	NULL
stages	NULL
the	NULL
dying	NULL
cells	NULL
become	NULL
fragmented	NULL
into	NULL
apoptotic	NULL
bodies	NULL
,	NULL
which	NULL
are	NULL
rapidly	NULL
eliminated	NULL
by	NULL
phagocytic	NULL
cells	NULL
without	NULL
eliciting	NULL
significant	NULL
inflammatory	NULL
damage	NULL
to	NULL
surrounding	NULL
cells	NULL
.	NULL

To	NULL
evaluate	NULL
whether	NULL
15d-PGJ	NULL
,	NULL
kills	NULL
B	NULL
cells	NULL
by	NULL
inducing	NULL
cell	NULL
death	NULL
in	NULL
an	NULL
apoptotic	NULL
fashion	NULL
we	NULL
first	NULL
examined	NULL
the	NULL
translocation	NULL
of	NULL
phosphatidylserine	NULL
from	NULL
the	NULL
inner	NULL
leaflet	NULL
of	NULL
the	NULL
plasma	NULL
membrane	NULL
to	NULL
the	NULL
outer	NULL
leaflet	NULL
by	NULL
annexin	NULL
V-FITC	NULL
labeling	NULL
.	NULL

Annexin	NULL
V	NULL
is	NULL
a	NULL
Ca*	NULL
*	NULL
-dependent	NULL
,	NULL
phospholipid-binding	NULL
protein	NULL
with	NULL
high	NULL
affinity	NULL
for	NULL
phosphatidylserine	NULL
(	NULL
29	NULL
)	NULL
.	NULL

Annexin	NULL
V-FITC	NULL
in	NULL
concert	NULL
with	NULL
flow	NULL
cytometry	NULL
is	NULL
a	NULL
sensitive	NULL
method	NULL
to	NULL
detect	NULL
cells	NULL
that	NULL
are	NULL
undergoing	NULL
early	NULL
phases	NULL
of	NULL
apoptosis	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
.	NULL

WEHI-231	NULL
cells	NULL
were	NULL
incubated	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
medium	NULL
or	NULL
the	NULL
PPAR-y	NULL
agonists	NULL
,	NULL
15d-PGJ	NULL
,	NULL
(	NULL
1	NULL
uM	NULL
)	NULL
and	NULL
troglitazone	NULL
(	NULL
10	NULL
uM	NULL
;	NULL
Fig	NULL
.	NULL

6	NULL
,	NULL
A	NULL
,	NULL
B	NULL
,	NULL
and	NULL
C	NULL
,	NULL
respectively	NULL
)	NULL
,	NULL
and	NULL
the	NULL
non-PPAR-y	NULL
agonists	NULL
,	NULL
WY14,643	NULL
and	NULL
PGF	NULL
;	NULL
,	NULL
,	NULL
,	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Samples	NULL
were	NULL
labeled	NULL
simultaneously	NULL
with	NULL
annexin	NULL
V-FITC	NULL
and	NULL
PI	NULL
.	NULL

The	NULL
viable	NULL
cells	NULL
depicted	NULL
in	NULL
Fig	NULL
.	NULL

6A	NULL
(	NULL
box	NULL
3	NULL
)	NULL
are	NULL
double	NULL
negative	NULL
(	NULL
FITC-/PI~	NULL
)	NULL
.	NULL

Cells	NULL
at	NULL
an	NULL
early	NULL
stage	NULL
of	NULL
apoptosis	NULL
are	NULL
positive	NULL
for	NULL
FITC	NULL
but	NULL
negative	NULL
for	NULL
6107	NULL
'01	NULL
Aepy	NULL
uo	NULL
isan	NULL
$	NULL
4q	NULL
310	NULL
founwurrf'mmm//	NULL
:	NULL
dyy	NULL
wo	NULL
papeojumoG	NULL
6944	NULL
PPAR-y	NULL
ON	NULL
B-LINEAGE	NULL
CELLS	NULL
A.	NULL
gu	NULL
a	NULL
8	NULL
Rh	NULL
I	NULL
o	NULL
T	NULL
=	NULL
y=	NULL
<	NULL
4	NULL
3	NULL
0	NULL
S	NULL
o	NULL
-C	NULL
a	NULL
-14	NULL
p	NULL
&	NULL
e	NULL
0	NULL
[	NULL
«	NULL
]	NULL
ju	NULL
m	NULL
&	NULL
<	NULL
4	NULL
U	NULL
&	NULL
a=	NULL
m	NULL
e	NULL
o	NULL
Ld	NULL
3	NULL
m	NULL
o	NULL
-	NULL
>	NULL
&	NULL
67kDa	NULL
--	NULL
»	NULL
a	NULL
>	NULL
anny	NULL
.	NULL

.	NULL

/	NULL
18	NULL
o	NULL
B	NULL
.	NULL

16	NULL
o	NULL
1	NULL
4	NULL
0	NULL
120	NULL
Ia	NULL
&	NULL
100	NULL
A	NULL
£	NULL
g	NULL
s	NULL
0	NULL
o	NULL
.2	NULL
e	NULL
0	NULL
L-8	NULL
C	NULL
C	NULL
-	NULL
40	NULL
°	NULL
B	NULL
cells	NULL
j	NULL
70273	NULL
-	NULL
CH3	NULL
1	NULL
|	NULL
ECH408	NULL
1	NULL
~	NULL
W	NULL
EHI-23	NULL
1	NULL
|	NULL
BAL-17	NULL
-	NULL
CH12	NULL
-	NULL
550	NULL
‘	NULL
CGH/lOT	NULL
‘	NULL
l	NULL
?	NULL

‘	NULL
FIGURE	NULL
2	NULL
.	NULL

A	NULL
,	NULL
B-lineage	NULL
cells	NULL
express	NULL
PPAR-y	NULL
protein	NULL
.	NULL

Fifteen	NULL
micrograms	NULL
of	NULL
total	NULL
cellular	NULL
protein	NULL
was	NULL
fractionated	NULL
by	NULL
10	NULL
%	NULL
SDS-PAGE	NULL
and	NULL
electrophoretically	NULL
transferred	NULL
to	NULL
a	NULL
Hybond-Extra	NULL
nitrocellulose	NULL
membrane	NULL
(	NULL
see	NULL
Materials	NULL
and	NULL
Methods	NULL
)	NULL
.	NULL

B	NULL
lymphomas	NULL
and	NULL
controls	NULL
were	NULL
all	NULL
cultivated	NULL
and	NULL
lysed	NULL
in	NULL
the	NULL
same	NULL
experiment	NULL
.	NULL

Membranes	NULL
were	NULL
incubated	NULL
with	NULL
anti-PPAR-y	NULL
polyclonal	NULL
Ab	NULL
,	NULL
washed	NULL
,	NULL
and	NULL
incubated	NULL
with	NULL
a	NULL
goat	NULL
anti-rabbit-HRP	NULL
conjugate	NULL
.	NULL

Bands	NULL
were	NULL
visualized	NULL
with	NULL
ECL	NULL
.	NULL

B	NULL
,	NULL
PPAR-y	NULL
protein	NULL
levels	NULL
did	NULL
not	NULL
vary	NULL
among	NULL
the	NULL
B	NULL
lymphoma	NULL
cell	NULL
lines	NULL
.	NULL

The	NULL
relative	NULL
intensities	NULL
of	NULL
three	NULL
separate	NULL
PPAR-y	NULL
Western	NULL
blots	NULL
using	NULL
the	NULL
same	NULL
assortment	NULL
of	NULL
B	NULL
cell	NULL
lymphomas	NULL
and	NULL
control	NULL
cell	NULL
lines	NULL
were	NULL
analyzed	NULL
and	NULL
plotted	NULL
.	NULL

PI	NULL
(	NULL
FITC	NULL
*/PI~	NULL
;	NULL
box	NULL
4	NULL
)	NULL
.	NULL

WEHI-231	NULL
cells	NULL
treated	NULL
with	NULL
15d-PGJ	NULL
,	NULL
;	NULL
,	NULL
or	NULL
troglitazone	NULL
showed	NULL
a	NULL
population	NULL
of	NULL
cells	NULL
that	NULL
was	NULL
apoptotic	NULL
.	NULL

Also	NULL
shown	NULL
(	NULL
box	NULL
2	NULL
)	NULL
were	NULL
cells	NULL
that	NULL
were	NULL
double	NULL
positive	NULL
(	NULL
FITC	NULL
*/PI	NULL
*	NULL
)	NULL
.	NULL

These	NULL
cells	NULL
were	NULL
at	NULL
later	NULL
stages	NULL
of	NULL
apoptosis	NULL
and	NULL
showed	NULL
evidence	NULL
of	NULL
necrosis	NULL
,	NULL
as	NULL
they	NULL
were	NULL
permeable	NULL
to	NULL
PI	NULL
.	NULL

According	NULL
to	NULL
these	NULL
data	NULL
both	NULL
PPAR-y	NULL
agonists	NULL
induced	NULL
apoptosis	NULL
in	NULL
WEHI-231	NULL
cells	NULL
.	NULL

Fig	NULL
.	NULL

7	NULL
shows	NULL
similar	NULL
results	NULL
for	NULL
CH31	NULL
cells	NULL
that	NULL
were	NULL
incubated	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
medium	NULL
or	NULL
the	NULL
PPAR-y	NULL
agonists	NULL
,	NULL
15d-PGJ	NULL
,	NULL
(	NULL
1	NULL
wM	NULL
)	NULL
,	NULL
ciglitazone	NULL
(	NULL
10	NULL
wM	NULL
)	NULL
,	NULL
and	NULL
troglitazone	NULL
(	NULL
10	NULL
uM	NULL
;	NULL
Fig	NULL
.	NULL

7	NULL
,	NULL
A	NULL
,	NULL
B	NULL
,	NULL
C	NULL
,	NULL
and	NULL
D	NULL
,	NULL
respectively	NULL
)	NULL
,	NULL
and	NULL
the	NULL
non-PPAR-y	NULL
agonists	NULL
,	NULL
WY14,643	NULL
and	NULL
PGF	NULL
;	NULL
,	NULL
,	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

CH31	NULL
cells	NULL
treated	NULL
with	NULL
15d-PGJ	NULL
;	NULL
,	NULL
,	NULL
ciglitazone	NULL
,	NULL
or	NULL
troglitazone	NULL
showed	NULL
a	NULL
population	NULL
of	NULL
cells	NULL
that	NULL
was	NULL
apoptotic	NULL
.	NULL

According	NULL
to	NULL
these	NULL
data	NULL
PPAR-y	NULL
agonists	NULL
induced	NULL
apoptosis	NULL
in	NULL
CH31	NULL
cells	NULL
.	NULL

In	NULL
the	NULL
final	NULL
stages	NULL
of	NULL
apoptosis	NULL
,	NULL
dying	NULL
cells	NULL
become	NULL
fragmented	NULL
into	NULL
apoptotic	NULL
bodies	NULL
,	NULL
which	NULL
are	NULL
rapidly	NULL
eliminated	NULL
by	NULL
phagocytic	NULL
cells	NULL
without	NULL
eliciting	NULL
significant	NULL
inflammatory	NULL
damage	NULL
to	NULL
surrounding	NULL
cells	NULL
.	NULL

To	NULL
further	NULL
confirm	NULL
that	NULL
PPAR-y	NULL
agonists	NULL
are	NULL
in	NULL
ducing	NULL
cell	NULL
death	NULL
in	NULL
an	NULL
apoptotic	NULL
fashion	NULL
we	NULL
examined	NULL
the	NULL
incorporation	NULL
of	NULL
biotin-dUTP	NULL
(	NULL
BdUTP	NULL
)	NULL
by	NULL
TUNEL	NULL
assay	NULL
.	NULL

Fig	NULL
.	NULL

6	NULL
shows	NULL
the	NULL
incorporation	NULL
of	NULL
BdUTP	NULL
detected	NULL
by	NULL
a	NULL
biotin-streptavidin-per-oxidase	NULL
technique	NULL
with	NULL
aminoethylcarbazole	NULL
as	NULL
a	NULL
chromogen	NULL
.	NULL

WEHI-231	NULL
or	NULL
CH31	NULL
cells	NULL
were	NULL
incubated	NULL
with	NULL
nothing	NULL
(	NULL
Figs	NULL
.	NULL

6D	NULL
and	NULL
respectively	NULL
)	NULL
,	NULL
PPAR-y	NULL
agonists	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
,	NULL
E	NULL
and	NULL
F	NULL
,	NULL
and	NULL
Fig	NULL
.	NULL

7	NULL
,	NULL
F-H	NULL
,	NULL
respectively	NULL
)	NULL
or	NULL
with	NULL
a	NULL
negative	NULL
control	NULL
reagent	NULL
(	NULL
PPAR-	NULL
«	NULL
agonist	NULL
or	NULL
PGF	NULL
;	NULL
,	NULL
,	NULL
,	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
for	NULL
6-12	NULL
h.	NULL
Only	NULL
samples	NULL
that	NULL
were	NULL
treated	NULL
with	NULL
15d-PGJ	NULL
,	NULL
(	NULL
Figs	NULL
.	NULL

6E	NULL
and	NULL
7F	NULL
)	NULL
,	NULL
ciglitazone	NULL
(	NULL
Fig	NULL
.	NULL

7C	NULL
)	NULL
,	NULL
or	NULL
troglitazone	NULL
(	NULL
Figs	NULL
.	NULL

6F	NULL
and	NULL
7H7	NULL
)	NULL
demonstrated	NULL
a	NULL
red	NULL
nuclear	NULL
staining	NULL
that	NULL
was	NULL
not	NULL
present	NULL
in	NULL
the	NULL
control	NULL
groups	NULL
.	NULL

Also	NULL
included	NULL
in	NULL
this	NULL
experiment	NULL
were	NULL
thymocytes	NULL
treated	NULL
with	NULL
dexamethasone	NULL
(	NULL
0.1	NULL
wM	NULL
)	NULL
as	NULL
a	NULL
positive	NULL
control	NULL
for	NULL
apoptosis	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Membrane	NULL
blebbing	NULL
and	NULL
nuclear	NULL
condensation	NULL
were	NULL
observed	NULL
only	NULL
in	NULL
samples	NULL
treated	NULL
with	NULL
PPAR-y	NULL
agonists	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
,	NULL
E	NULL
and	NULL
F	NULL
,	NULL
and	NULL
Fig	NULL
.	NULL

7	NULL
,	NULL
F-H	NULL
)	NULL
.	NULL

No	NULL
morphological	NULL
changes	NULL
were	NULL
observed	NULL
in	NULL
samples	NULL
treated	NULL
with	NULL
non-PPAR-y	NULL
agonists	NULL
.	NULL

Similar	NULL
findings	NULL
have	NULL
been	NULL
obtained	NULL
in	NULL
BAL-17	NULL
and	NULL
ECH.408.1	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

6107	NULL
'01	NULL
Aepy	NULL
uo	NULL
isan	NULL
$	NULL
4q	NULL
310	NULL
founwurrf'mmm//	NULL
:	NULL
dyy	NULL
wo	NULL
papeojumoG	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
FIGURE	NULL
3	NULL
.	NULL

-	NULL
15d-PGJ	NULL
,	NULL
induces	NULL
growth	NULL
inhibition	NULL
of	NULL
B-lineage	NULL
cells	NULL
.	NULL

[	NULL
°H	NULL
]	NULL
Thymidine	NULL
incorporation	NULL
assay	NULL
of	NULL
B-lineage	NULL
cells	NULL
and	NULL
C3H10T	NULL
1/2	NULL
fibroblast-like	NULL
cells	NULL
treated	NULL
with	NULL
15d-PGJ	NULL
;	NULL
,	NULL
or	NULL
PGF	NULL
»	NULL
,	NULL
at	NULL
1	NULL
wM	NULL
for	NULL
48	NULL
h.	NULL
After	NULL
the	NULL
initial	NULL
24-h	NULL
incubation	NULL
period	NULL
,	NULL
cells	NULL
were	NULL
pulsed	NULL
with	NULL
1	NULL
wCi/well	NULL
of	NULL
[	NULL
°H	NULL
]	NULL
thymidine	NULL
.	NULL

Plates	NULL
were	NULL
harvested	NULL
with	NULL
a	NULL
Micromate	NULL
196	NULL
cell	NULL
harvester	NULL
,	NULL
and	NULL
incorporation	NULL
of	NULL
[	NULL
°HJthymidine	NULL
was	NULL
determined	NULL
with	NULL
a	NULL
Matrix	NULL
96	NULL
direct	NULL
beta	NULL
counter	NULL
(	NULL
see	NULL
Materials	NULL
and	NULL
Methods	NULL
)	NULL
.	NULL

These	NULL
data	NULL
were	NULL
graphed	NULL
as	NULL
a	NULL
percentage	NULL
of	NULL
the	NULL
vehicle	NULL
(	NULL
DMSO	NULL
)	NULL
control	NULL
response	NULL
.	NULL

Cell	NULL
line	NULL
C3H10T1/2	NULL
70273	NULL
CH31	NULL
ECH.408.1	NULL
WEHI-231	NULL
CH12	NULL
BAL-17	NULL
J558	NULL
Normal	NULL
Stage	NULL
of	NULL
Differentiation	NULL
6945	NULL
Control	NULL
Pre-B	NULL
cell	NULL
Immature	NULL
Immature	NULL
Immature	NULL
Mature	NULL
Mature	NULL
Plasma	NULL
Naive	NULL
20	NULL
40	NULL
60	NULL
80	NULL
Percent	NULL
Control	NULL
(	NULL
°H-Thymidine	NULL
)	NULL
100	NULL
120	NULL
|	NULL
he	NULL
PGF	NULL
;	NULL
,	NULL
Cell	NULL
line	NULL
-	NULL
Stage	NULL
of	NULL
Differentiation	NULL
C3H10T1/2	NULL
Control	NULL
~	NULL
F2	NULL
7028	NULL
``	NULL
--	NULL
'	NULL
``	NULL
CH31	NULL
Immature	NULL
W§§M	NULL
'	NULL
ECH.408.1	NULL
Immature	NULL
fs	NULL
§M\§N§§9	NULL
WEHIL-231	NULL
Immature	NULL
_	NULL
7	NULL
E	NULL
CH12	NULL
Mature	NULL
&	NULL
z	NULL
BAL-17	NULL
Mature	NULL
a	NULL
s	NULL
sp	NULL
J558	NULL
Plasma	NULL
...	NULL
p	NULL
Normal	NULL
Naive	NULL
“	NULL
us	NULL
?	NULL

t	NULL
I	NULL
1	NULL
1	NULL
I	NULL
1	NULL
I	NULL
I	NULL
I	NULL
I	NULL
I	NULL
I	NULL
I	NULL
1	NULL
I	NULL
I	NULL
I	NULL
I	NULL
0	NULL
2	NULL
'	NULL
0	NULL
4	NULL
'	NULL
0	NULL
BIO	NULL
310	NULL
1	NULL
&	NULL
0	NULL
1	NULL
&	NULL
0	NULL
Percent	NULL
Control	NULL
(	NULL
MTT	NULL
)	NULL
I	NULL
150-964	NULL
PGF	NULL
,	NULL
FIGURE	NULL
4	NULL
.	NULL

15d-PGJ	NULL
,	NULL
kills	NULL
B-lineage	NULL
cells	NULL
.	NULL

A	NULL
viability	NULL
assay	NULL
was	NULL
performed	NULL
on	NULL
B-lineage	NULL
cells	NULL
and	NULL
C3H10TI1/2	NULL
cells	NULL
treated	NULL
with	NULL
15d-PGJ	NULL
,	NULL
or	NULL
PGF	NULL
;	NULL
,	NULL
,	NULL
at	NULL
1	NULL
wM	NULL
for	NULL
48	NULL
h.	NULL
B-lineage	NULL
cells	NULL
are	NULL
homogeneous	NULL
in	NULL
their	NULL
sensitivity	NULL
to	NULL
15d-PGJ	NULL
;	NULL
.	NULL

In	NULL
con-trast	NULL
,	NULL
C3H10T1/2	NULL
are	NULL
not	NULL
killed	NULL
by	NULL
15d-PGJ	NULL
;	NULL
,	NULL
.	NULL

After	NULL
48	NULL
h	NULL
of	NULL
incubation	NULL
a	NULL
solution	NULL
of	NULL
5	NULL
mg/ml	NULL
of	NULL
MTT	NULL
was	NULL
added	NULL
.	NULL

Plates	NULL
were	NULL
kept	NULL
at	NULL
37°C	NULL
for	NULL
4	NULL
h	NULL
,	NULL
then	NULL
centrifuged	NULL
,	NULL
and	NULL
the	NULL
precipitate	NULL
was	NULL
dissolved	NULL
by	NULL
adding	NULL
200	NULL
l	NULL
of	NULL
DMSO	NULL
to	NULL
each	NULL
well	NULL
.	NULL

Plates	NULL
were	NULL
read	NULL
at	NULL
570	NULL
nm	NULL
on	NULL
an	NULL
ELISA	NULL
reader	NULL
(	NULL
see	NULL
Materials	NULL
and	NULL
Methods	NULL
)	NULL
.	NULL

These	NULL
data	NULL
were	NULL
graphed	NULL
as	NULL
a	NULL
percentage	NULL
of	NULL
the	NULL
DMSO	NULL
control	NULL
response	NULL
.	NULL

6107	NULL
'01	NULL
Aepy	NULL
uo	NULL
isan	NULL
$	NULL
4q	NULL
310	NULL
founwurrf'mmm//	NULL
:	NULL
dyy	NULL
wo	NULL
papeojumoG	NULL
6946	NULL
120	NULL
100	NULL
€	NULL
3	NULL
E	NULL
2	NULL
80	NULL
n	NULL
£	NULL
e	NULL
B	NULL
E	NULL
60	NULL
~	NULL
8	NULL
@	NULL
ror	NULL
,	NULL
,	NULL
F	NULL
$	NULL
0	NULL
ao	NULL
4	NULL
Am	NULL
,	NULL
Ciglitazone	NULL
&	NULL
0	NULL
Troglitazone	NULL
20	NULL
3k	NULL
wyi4eas	NULL
o	NULL
-	NULL
J	NULL
1.00E-8	NULL
1.00E-7	NULL
1.00E-6	NULL
1.00E-5	NULL
1.00E-4	NULL
Dose	NULL
(	NULL
Molar	NULL
)	NULL
FIGURE	NULL
5	NULL
.	NULL

PPAR-y	NULL
agonists	NULL
(	NULL
ciglitazone	NULL
and	NULL
troglitazone	NULL
)	NULL
mimic	NULL
the	NULL
effect	NULL
that	NULL
15d-PGJ	NULL
;	NULL
,	NULL
has	NULL
on	NULL
CH31	NULL
cells	NULL
.	NULL

Non-PPAR-y	NULL
agonists	NULL
(	NULL
PGF	NULL
»	NULL
,	NULL
and	NULL
WY14,643	NULL
)	NULL
have	NULL
no	NULL
antiproliferative	NULL
effect	NULL
on	NULL
CH31	NULL
cells	NULL
.	NULL

A	NULL
dine	NULL
incorporation	NULL
assay	NULL
was	NULL
performed	NULL
on	NULL
CH31	NULL
cells	NULL
treated	NULL
with	NULL
PPAR-y	NULL
agonists	NULL
and	NULL
negative	NULL
control	NULL
agonists	NULL
for	NULL
48	NULL
h.	NULL
After	NULL
the	NULL
initial	NULL
24-h	NULL
incubation	NULL
period	NULL
,	NULL
cells	NULL
were	NULL
pulsed	NULL
with	NULL
1	NULL
wCi/well	NULL
of	NULL
[	NULL
°HJthymidine	NULL
.	NULL

Plates	NULL
were	NULL
harvested	NULL
with	NULL
a	NULL
Micromate	NULL
196-cell	NULL
harvester	NULL
,	NULL
and	NULL
incorporation	NULL
of	NULL
[	NULL
°H	NULL
]	NULL
thymidine	NULL
was	NULL
determined	NULL
with	NULL
a	NULL
Matrix	NULL
96	NULL
direct	NULL
beta	NULL
counter	NULL
(	NULL
see	NULL
Materials	NULL
and	NULL
Methods	NULL
)	NULL
.	NULL

These	NULL
data	NULL
were	NULL
graphed	NULL
as	NULL
a	NULL
percentage	NULL
of	NULL
the	NULL
DMSO	NULL
control	NULL
response	NULL
.	NULL

PGF	NULL
,	NULL
,	NULL
,	NULL
abrogates	NULL
the	NULL
induction	NULL
of	NULL
apoptosis	NULL
induced	NULL
by	NULL
PPAR-y	NULL
agonists	NULL
on	NULL
B	NULL
lymphoma	NULL
cells	NULL
PGF	NULL
;	NULL
,	NULL
,	NULL
was	NULL
recently	NULL
proposed	NULL
to	NULL
modulate	NULL
the	NULL
adipogenic	NULL
effect	NULL
of	NULL
15d-PGJ	NULL
,	NULL
(	NULL
15	NULL
,	NULL
30	NULL
)	NULL
.	NULL

The	NULL
mechanism	NULL
by	NULL
which	NULL
PGF	NULL
;	NULL
,	NULL
,	NULL
interfered	NULL
with	NULL
PPAR-y/PPAR-y	NULL
agonist	NULL
interaction	NULL
involved	NULL
MAPK	NULL
(	NULL
30	NULL
)	NULL
.	NULL

To	NULL
further	NULL
evaluate	NULL
the	NULL
mechanisms	NULL
involved	NULL
in	NULL
the	NULL
interaction	NULL
between	NULL
15d-PGJ	NULL
,	NULL
and	NULL
PPAR-y	NULL
in	NULL
B	NULL
lymphocytes	NULL
,	NULL
we	NULL
preincubated	NULL
B	NULL
lymphoma	NULL
cells	NULL
(	NULL
CH31	NULL
,	NULL
ECH.408.1	NULL
,	NULL
and	NULL
J558	NULL
)	NULL
with	NULL
PGF	NULL
;	NULL
,	NULL
,	NULL
(	NULL
0.1	NULL
uM	NULL
)	NULL
for	NULL
1	NULL
h	NULL
before	NULL
treatment	NULL
with	NULL
15d-PGJ	NULL
,	NULL
(	NULL
1	NULL
wM	NULL
)	NULL
.	NULL

[	NULL
H	NULL
]	NULL
thymidine	NULL
incorporation	NULL
assays	NULL
were	NULL
used	NULL
to	NULL
determine	NULL
whether	NULL
PGF	NULL
,	NULL
,	NULL
,	NULL
modulated	NULL
the	NULL
activity	NULL
of	NULL
15d-PGJ	NULL
,	NULL
(	NULL
Fig	NULL
.	NULL

8A	NULL
)	NULL
.	NULL

PGF	NULL
;	NULL
,	NULL
,	NULL
strongly	NULL
blocked	NULL
the	NULL
inhibitory	NULL
action	NULL
of	NULL
15d-PGJ	NULL
,	NULL
on	NULL
these	NULL
B	NULL
lymphoma	NULL
cells	NULL
,	NULL
allowing	NULL
cell	NULL
proliferation	NULL
to	NULL
proceed	NULL
normally	NULL
,	NULL
PPAR-y	NULL
ON	NULL
B-LINEAGE	NULL
CELLS	NULL
as	NULL
detected	NULL
by	NULL
incorporation	NULL
of	NULL
[	NULL
°H	NULL
]	NULL
thymidine	NULL
.	NULL

This	NULL
was	NULL
interest-ing	NULL
,	NULL
as	NULL
PGF	NULL
,	NULL
was	NULL
not	NULL
known	NULL
to	NULL
have	NULL
any	NULL
effect	NULL
on	NULL
lymphocytes	NULL
.	NULL

We	NULL
next	NULL
examined	NULL
the	NULL
effect	NULL
that	NULL
these	NULL
prostanoids	NULL
had	NULL
on	NULL
MAPK	NULL
activation	NULL
of	NULL
B-lineage	NULL
cells	NULL
.	NULL

Fig	NULL
.	NULL

8B	NULL
shows	NULL
the	NULL
dramatic	NULL
changes	NULL
in	NULL
the	NULL
levels	NULL
of	NULL
MAPK	NULL
activity	NULL
reflecting	NULL
the	NULL
opposing	NULL
effects	NULL
of	NULL
PGF	NULL
,	NULL
and	NULL
15d-PGJ	NULL
;	NULL
,	NULL
.	NULL

Treatment	NULL
with	NULL
15d-PGJ	NULL
,	NULL
(	NULL
1	NULL
wM	NULL
)	NULL
induced	NULL
a	NULL
massive	NULL
increase	NULL
in	NULL
MAPK	NULL
(	NULL
Fig	NULL
.	NULL

8B	NULL
)	NULL
.	NULL

This	NULL
was	NULL
a	NULL
rather	NULL
surprising	NULL
finding	NULL
,	NULL
as	NULL
15d-PGJ	NULL
;	NULL
,	NULL
is	NULL
not	NULL
known	NULL
to	NULL
activate	NULL
MAPK	NULL
in	NULL
nonhe-mopoietic	NULL
cells	NULL
.	NULL

PGF	NULL
,	NULL
,	NULL
,	NULL
(	NULL
0.1	NULL
uM	NULL
)	NULL
,	NULL
however	NULL
,	NULL
is	NULL
known	NULL
to	NULL
activate	NULL
MAPK	NULL
(	NULL
30	NULL
)	NULL
and	NULL
does	NULL
so	NULL
in	NULL
B-lineage	NULL
cells	NULL
(	NULL
Fig	NULL
.	NULL

8B	NULL
)	NULL
.	NULL

Pretreatment	NULL
with	NULL
PGF	NULL
;	NULL
,	NULL
,	NULL
followed	NULL
by	NULL
15d-PGJ	NULL
,	NULL
(	NULL
1	NULL
wM	NULL
)	NULL
dramatically	NULL
reduced	NULL
the	NULL
ability	NULL
of	NULL
15d-PGJ	NULL
,	NULL
to	NULL
induce	NULL
MAPK	NULL
activation	NULL
(	NULL
Fig	NULL
.	NULL

8B	NULL
)	NULL
.	NULL

Levels	NULL
of	NULL
MAPK	NULL
activation	NULL
of	NULL
untreated	NULL
cells	NULL
were	NULL
negligible	NULL
.	NULL

Discussion	NULL
This	NULL
paper	NULL
presents	NULL
the	NULL
finding	NULL
that	NULL
B	NULL
lymphocytes	NULL
and	NULL
B	NULL
lymphoma	NULL
cells	NULL
express	NULL
mRNA	NULL
and	NULL
protein	NULL
for	NULL
PPAR-y	NULL
.	NULL

Herein	NULL
is	NULL
the	NULL
first	NULL
report	NULL
demonstrating	NULL
the	NULL
expression	NULL
of	NULL
PPAR-y	NULL
in	NULL
B	NULL
cells	NULL
and	NULL
the	NULL
effects	NULL
of	NULL
this	NULL
nuclear	NULL
receptor	NULL
on	NULL
B-lineage	NULL
cells	NULL
.	NULL

Based	NULL
on	NULL
current	NULL
models	NULL
of	NULL
PPARs	NULL
(	NULL
9	NULL
,	NULL
25	NULL
)	NULL
,	NULL
the	NULL
PPAR-y	NULL
agonist	NULL
15d-PGJ	NULL
,	NULL
interacts	NULL
with	NULL
B	NULL
lymphocytes	NULL
via	NULL
the	NULL
nuclear	NULL
receptor	NULL
PPAR-y	NULL
.	NULL

The	NULL
identification	NULL
of	NULL
15d-PGJ	NULL
;	NULL
,	NULL
as	NULL
a	NULL
ligand	NULL
for	NULL
PPAR-y	NULL
on	NULL
B	NULL
lymphocytes	NULL
implicates	NULL
a	NULL
novel	NULL
pathway	NULL
in	NULL
the	NULL
interaction	NULL
between	NULL
PGs	NULL
and	NULL
B	NULL
cells	NULL
.	NULL

The	NULL
precise	NULL
molecular	NULL
pathways	NULL
by	NULL
which	NULL
cy-clopentanone	NULL
PGs	NULL
inhibit	NULL
cell	NULL
growth	NULL
and	NULL
tumorigenicity	NULL
are	NULL
un-known	NULL
.	NULL

This	NULL
paper	NULL
provides	NULL
a	NULL
mechanism	NULL
by	NULL
which	NULL
may	NULL
have	NULL
an	NULL
anti-cancer	NULL
effect	NULL
by	NULL
binding	NULL
PPAR-y	NULL
on	NULL
B	NULL
lymphoma	NULL
cells	NULL
.	NULL

Whereas	NULL
activation	NULL
of	NULL
PPAR-y	NULL
on	NULL
macrophages	NULL
antagonizes	NULL
the	NULL
production	NULL
of	NULL
proinflammatory	NULL
cytokines	NULL
such	NULL
as	NULL
TNF-a	NULL
(	NULL
10	NULL
)	NULL
,	NULL
on	NULL
B	NULL
lymphomas	NULL
and	NULL
B	NULL
lymphocytes	NULL
it	NULL
induces	NULL
apoptosis	NULL
.	NULL

PGD	NULL
,	NULL
the	NULL
15d-PGJ	NULL
,	NULL
precursor	NULL
,	NULL
is	NULL
the	NULL
major	NULL
prostanoid	NULL
in	NULL
bone	NULL
marrow	NULL
and	NULL
spleen	NULL
extracts	NULL
.	NULL

Concentrations	NULL
in	NULL
these	NULL
tissues	NULL
are	NULL
reported	NULL
to	NULL
be	NULL
at	NULL
least	NULL
as	NULL
high	NULL
as	NULL
10	NULL
wM	NULL
(	NULL
4	NULL
)	NULL
,	NULL
a	NULL
concentration	NULL
likely	NULL
to	NULL
be	NULL
effective	NULL
on	NULL
B-lineage	NULL
cells	NULL
.	NULL

Interestingly	NULL
,	NULL
PPAR-y	NULL
has	NULL
been	NULL
detected	NULL
by	NULL
in	NULL
situ	NULL
hybridization	NULL
and	NULL
immunohistochemistry	NULL
in	NULL
B	NULL
lymphocyte	NULL
proliferation	NULL
centers	NULL
of	NULL
the	NULL
spleen	NULL
and	NULL
the	NULL
Peyer	NULL
's	NULL
patches	NULL
,	NULL
indicating	NULL
a	NULL
potential	NULL
role	NULL
in	NULL
regulating	NULL
immune	NULL
responses	NULL
(	NULL
31	NULL
)	NULL
.	NULL

Colocalization	NULL
of	NULL
PPAR-y	NULL
and	NULL
PGD	NULL
,	NULL
in	NULL
secondary	NULL
lymphoid	NULL
organs	NULL
suggests	NULL
that	NULL
PGD	NULL
,	NULL
metabolites	NULL
such	NULL
as	NULL
15d-PGJ	NULL
,	NULL
may	NULL
serve	NULL
as	NULL
PPAR-y	NULL
ligands	NULL
in	NULL
B	NULL
lymphocytes	NULL
in	NULL
these	NULL
tissues	NULL
.	NULL

Therefore	NULL
,	NULL
the	NULL
new	NULL
data	NULL
reported	NULL
herein	NULL
showing	NULL
unequivocal	NULL
PPAR-y	NULL
WEHI-231	NULL
Cells	NULL
alone	NULL
FIGURE	NULL
6	NULL
.	NULL

-	NULL
PPAR-y	NULL
agonists	NULL
induce	NULL
apoptosis	NULL
in	NULL
WEHI-231	NULL
B	NULL
lymphoma	NULL
cells	NULL
.	NULL

WEHI-231	NULL
cells	NULL
were	NULL
incubated	NULL
with	NULL
PPAR-y	NULL
agonists	NULL
or	NULL
with	NULL
negative	NULL
control	NULL
agonists	NULL
(	NULL
e.g	NULL
.	NULL

,	NULL
PPAR-	NULL
«	NULL
agonist	NULL
)	NULL
for	NULL
6-12	NULL
h.	NULL
Fresh	NULL
untreated	NULL
cells	NULL
(	NULL
A	NULL
and	NULL
D	NULL
)	NULL
or	NULL
those	NULL
incubated	NULL
with	NULL
15d-PGJ	NULL
,	NULL
(	NULL
1	NULL
M	NULL
;	NULL
B	NULL
and	NULL
E	NULL
)	NULL
or	NULL
troglitazone	NULL
(	NULL
10	NULL
uM	NULL
;	NULL
C	NULL
and	NULL
F	NULL
)	NULL
are	NULL
shown	NULL
.	NULL

Apoptosis	NULL
hallmarks	NULL
were	NULL
detected	NULL
by	NULL
annexin	NULL
V-FITC	NULL
(	NULL
B	NULL
and	NULL
C	NULL
)	NULL
and	NULL
were	NULL
confirmed	NULL
by	NULL
TUNEL	NULL
assay	NULL
(	NULL
E	NULL
and	NULL
F	NULL
;	NULL
see	NULL
Materials	NULL
and	NULL
Methods	NULL
)	NULL
.	NULL

No	NULL
annexin	NULL
WEHI-231	NULL
WEHI-231	NULL
15d-PGJ	NULL
,	NULL
tx	NULL
.	NULL

Troglitazone	NULL
tx	NULL
.	NULL

B.	NULL
C.	NULL
LOG	NULL
PI	NULL
LOG	NULL
PI	NULL
1000	NULL
.	NULL

1000	NULL
Los	NULL
FrTc	NULL
1080	NULL
LOG	NULL
FITC	NULL
V-FITC	NULL
labeling	NULL
or	NULL
BdUTP	NULL
incorporation	NULL
was	NULL
detected	NULL
on	NULL
samples	NULL
incubated	NULL
with	NULL
the	NULL
PPAR-a	NULL
agonist	NULL
WY14,643	NULL
and/or	NULL
with	NULL
PGF	NULL
,	NULL
6107	NULL
'01	NULL
Aepy	NULL
uo	NULL
isan	NULL
$	NULL
4q	NULL
310	NULL
founwurrf'mmm//	NULL
:	NULL
dyy	NULL
wo	NULL
papeojumoG	NULL
The	NULL
Journal	NULL
of	NULL
Immunology	NULL
6947	NULL
A.	NULL
CH31	NULL
B.	NULL
CH31	NULL
c.	NULL
CH31	NULL
p.	NULL
CH31	NULL
Cells	NULL
alone	NULL
15d-PGJ	NULL
,	NULL
tx	NULL
.	NULL

Ciglitazone	NULL
tx	NULL
.	NULL

Troglitazone	NULL
s	NULL
10c00/1600	NULL
vslaaaa/leeaa	NULL
o	NULL
10000	NULL
,	NULL
/10000	NULL
ieage/1ie000	NULL
§	NULL
i	NULL
3	NULL
1	NULL
a\	NULL
g	NULL
a	NULL
2	NULL
®	NULL
PI	NULL
3	NULL
1	NULL
j	NULL
a	NULL
«	NULL
1	NULL
1000	NULL
«	NULL
1	NULL
1000	NULL
Annexin	NULL
V	NULL
FITC	NULL
CH31	NULL
:	NULL
Cells	NULL
alone	NULL
CH31	NULL
;	NULL
:	NULL
15d-PGJ	NULL
,	NULL
CH31	NULL
:	NULL
Ciglitazone	NULL
CH31	NULL
:	NULL
Troglitazone	NULL
FIGURE	NULL
7	NULL
.	NULL

-	NULL
PPAR-y	NULL
agonists	NULL
induce	NULL
apoptosis	NULL
in	NULL
CH31	NULL
B	NULL
lymphoma	NULL
cells	NULL
.	NULL

CH31	NULL
cells	NULL
were	NULL
incubated	NULL
with	NULL
PPAR-y	NULL
agonists	NULL
or	NULL
with	NULL
negative	NULL
control	NULL
agonists	NULL
(	NULL
e.g	NULL
.	NULL

,	NULL
PPAR-a	NULL
agonist	NULL
)	NULL
for	NULL
6-12	NULL
h.	NULL
Fresh	NULL
untreated	NULL
cells	NULL
(	NULL
A	NULL
and	NULL
£	NULL
)	NULL
or	NULL
those	NULL
incubated	NULL
with	NULL
15d-PGJ	NULL
,	NULL
(	NULL
1	NULL
M	NULL
;	NULL
B	NULL
and	NULL
F	NULL
)	NULL
,	NULL
ciglitazone	NULL
(	NULL
10	NULL
uM	NULL
;	NULL
C	NULL
and	NULL
G	NULL
)	NULL
,	NULL
or	NULL
troglitazone	NULL
(	NULL
10	NULL
M	NULL
;	NULL
D	NULL
and	NULL
H	NULL
)	NULL
are	NULL
shown	NULL
.	NULL

Apoptosis	NULL
hallmarks	NULL
were	NULL
detected	NULL
by	NULL
annexin	NULL
V-FITC	NULL
(	NULL
B-D	NULL
)	NULL
and	NULL
were	NULL
confirmed	NULL
by	NULL
TUNEL	NULL
assay	NULL
(	NULL
F-H	NULL
;	NULL
see	NULL
Materials	NULL
and	NULL
Methods	NULL
)	NULL
.	NULL

No	NULL
annexin	NULL
V-FITC	NULL
labeling	NULL
or	NULL
BdUTP	NULL
incorporation	NULL
was	NULL
detected	NULL
on	NULL
samples	NULL
incubated	NULL
with	NULL
the	NULL
PPAR-	NULL
«	NULL
agonist	NULL
WY14,643	NULL
and/or	NULL
with	NULL
PGF	NULL
,	NULL
,	NULL
,	NULL
.	NULL

ECHA4O08.1	NULL
Relative	NULL
Density	NULL
J558	NULL
alc	NULL
,	NULL
``	NULL
Control	NULL
15d-PGJ	NULL
,	NULL
PGF	NULL
,	NULL
,	NULL
a	NULL
f	NULL
f	NULL
f	NULL
0	NULL
20	NULL
40	NULL
60	NULL
0	NULL
'	NULL
0	NULL
u	NULL
‘	NULL
m	NULL
do	NULL
Percent	NULL
Control	NULL
(	NULL
°H-Thymidine	NULL
)	NULL
PGF..+	NULL
15d-PGJ	NULL
,	NULL
§	NULL
PGF	NULL
.	NULL

DO	NULL
PGF	NULL
,	NULL
/15d-PGJ	NULL
,	NULL
-	NULL
W	NULL
15d4-PGy	NULL
,	NULL
FIGURE	NULL
8	NULL
.	NULL

-	NULL
PGF	NULL
;	NULL
,	NULL
,	NULL
abrogates	NULL
the	NULL
deleterious	NULL
effects	NULL
of	NULL
PPAR-y	NULL
agonist	NULL
on	NULL
B	NULL
lymphoma	NULL
cells	NULL
.	NULL

A	NULL
,	NULL
The	NULL
B	NULL
lymphoma	NULL
cells	NULL
CH31	NULL
,	NULL
ECH.408.1	NULL
,	NULL
and	NULL
1558	NULL
were	NULL
preincubated	NULL
with	NULL
PGF	NULL
,	NULL
,	NULL
,	NULL
(	NULL
0.1	NULL
uM	NULL
)	NULL
for	NULL
1	NULL
h	NULL
before	NULL
treatment	NULL
with	NULL
15d-PGJ	NULL
;	NULL
,	NULL
(	NULL
1	NULL
wM	NULL
)	NULL
for	NULL
24	NULL
h.	NULL
Cells	NULL
were	NULL
also	NULL
treated	NULL
with	NULL
only	NULL
15d-PGJ	NULL
,	NULL
or	NULL
PGF	NULL
;	NULL
,	NULL
,	NULL
.	NULL

B	NULL
lymphoma	NULL
cells	NULL
were	NULL
pulsed	NULL
with	NULL
1	NULL
uCi/well	NULL
of	NULL
[	NULL
°HJthymidine	NULL
(	NULL
see	NULL
Materials	NULL
and	NULL
Methods	NULL
)	NULL
.	NULL

B	NULL
,	NULL
After	NULL
treatment	NULL
with	NULL
medium	NULL
,	NULL
15d-PGJ	NULL
;	NULL
,	NULL
or	NULL
PGF	NULL
,	NULL
alone	NULL
or	NULL
with	NULL
PGF	NULL
;	NULL
,	NULL
,	NULL
plus	NULL
15d-PGJ	NULL
;	NULL
,	NULL
nuclei	NULL
from	NULL
J558	NULL
B	NULL
cells	NULL
were	NULL
harvested	NULL
.	NULL

Immunoprecipitation	NULL
and	NULL
Western	NULL
blot	NULL
of	NULL
phosphorylated	NULL
MAPK	NULL
were	NULL
performed	NULL
(	NULL
see	NULL
Materials	NULL
and	NULL
Methods	NULL
)	NULL
.	NULL

15d-PGJ	NULL
,	NULL
dramatically	NULL
induced	NULL
MAPK	NULL
activation	NULL
.	NULL

PGF	NULL
,	NULL
induced	NULL
a	NULL
more	NULL
modest	NULL
activation	NULL
of	NULL
MAPK	NULL
.	NULL

Pretreatment	NULL
with	NULL
PGF	NULL
;	NULL
,	NULL
,	NULL
caused	NULL
a	NULL
substantial	NULL
attenuation	NULL
of	NULL
the	NULL
15d-PGJ	NULL
,	NULL
-induced	NULL
MAPK	NULL
activation	NULL
.	NULL

6107	NULL
'01	NULL
Aepy	NULL
uo	NULL
isan	NULL
$	NULL
4q	NULL
310	NULL
founwurrf'mmm//	NULL
:	NULL
dyy	NULL
wos	NULL
papeojumog	NULL
6948	NULL
expression	NULL
by	NULL
B	NULL
cells	NULL
coupled	NULL
with	NULL
localization	NULL
of	NULL
PPAR-y	NULL
and	NULL
PGD	NULL
,	NULL
in	NULL
lymphoid	NULL
tissues	NULL
reveal	NULL
a	NULL
novel	NULL
regulatory	NULL
role	NULL
for	NULL
PPAR-y	NULL
.	NULL

In	NULL
contrast	NULL
to	NULL
other	NULL
PGs	NULL
such	NULL
as	NULL
PGE	NULL
,	NULL
that	NULL
promote	NULL
B	NULL
cell	NULL
differentiation	NULL
(	NULL
32	NULL
,	NULL
33	NULL
)	NULL
and	NULL
plasmacytomagenesis	NULL
(	NULL
34	NULL
,	NULL
35	NULL
)	NULL
,	NULL
PGD	NULL
,	NULL
/	NULL
15d-PGJ	NULL
,	NULL
may	NULL
inhibit	NULL
B	NULL
cell	NULL
development	NULL
by	NULL
rapidly	NULL
blunting	NULL
proliferation	NULL
and	NULL
killing	NULL
susceptible	NULL
cells	NULL
.	NULL

PGF	NULL
;	NULL
,	NULL
,	NULL
signals	NULL
through	NULL
a	NULL
cell	NULL
surface	NULL
receptor	NULL
and	NULL
does	NULL
not	NULL
activate	NULL
PPAR-y	NULL
(	NULL
9	NULL
,	NULL
25	NULL
)	NULL
.	NULL

PGF	NULL
;	NULL
,	NULL
,	NULL
has	NULL
an	NULL
inhibitory	NULL
effect	NULL
on	NULL
adipocyte	NULL
differentiation	NULL
,	NULL
which	NULL
involves	NULL
MAPK	NULL
(	NULL
15	NULL
,	NULL
30	NULL
)	NULL
.	NULL

In	NULL
our	NULL
investigation	NULL
PGF	NULL
,	NULL
,	NULL
,	NULL
strongly	NULL
modulated	NULL
the	NULL
deleterious	NULL
effect	NULL
that	NULL
15d-PGJ	NULL
,	NULL
had	NULL
on	NULL
B-lineage	NULL
cells	NULL
.	NULL

Therefore	NULL
,	NULL
15d-PGJ	NULL
;	NULL
,	NULL
is	NULL
not	NULL
simply	NULL
a	NULL
toxic	NULL
molecule	NULL
,	NULL
because	NULL
PGF	NULL
,	NULL
,	NULL
,	NULL
attenuates	NULL
its	NULL
proapoptotic	NULL
affects	NULL
.	NULL

We	NULL
were	NULL
surprised	NULL
to	NULL
see	NULL
that	NULL
15d-PGJ	NULL
,	NULL
induced	NULL
a	NULL
massive	NULL
MAPK	NULL
activation	NULL
.	NULL

PGF	NULL
,	NULL
,	NULL
,	NULL
pretreatment	NULL
caused	NULL
a	NULL
substantial	NULL
attenuation	NULL
of	NULL
the	NULL
15d-PGJ	NULL
,	NULL
-induced	NULL
MAPK	NULL
.	NULL

These	NULL
data	NULL
support	NULL
the	NULL
concept	NULL
that	NULL
the	NULL
mechanism	NULL
by	NULL
which	NULL
15d-PGJ	NULL
;	NULL
,	NULL
interacts	NULL
with	NULL
B	NULL
cells	NULL
involves	NULL
PPAR-y	NULL
.	NULL

However	NULL
,	NULL
we	NULL
can	NULL
not	NULL
disregard	NULL
the	NULL
possibility	NULL
that	NULL
15d-PGJ	NULL
,	NULL
may	NULL
have	NULL
other	NULL
effects	NULL
on	NULL
B-lineage	NULL
cells	NULL
that	NULL
may	NULL
be	NULL
PPAR-y	NULL
independent	NULL
,	NULL
as	NULL
reported	NULL
by	NULL
others	NULL
studying	NULL
microglial	NULL
inducible	NULL
NO	NULL
synthase	NULL
(	NULL
36	NULL
)	NULL
and	NULL
neutrophils	NULL
(	NULL
37	NULL
)	NULL
.	NULL

We	NULL
speculate	NULL
that	NULL
the	NULL
mechanism	NULL
by	NULL
which	NULL
PPAR-y	NULL
agonists	NULL
interact	NULL
with	NULL
B	NULL
lymphocytes	NULL
and	NULL
induce	NULL
apoptosis	NULL
involves	NULL
the	NULL
activation	NULL
of	NULL
MAPK	NULL
.	NULL

Additional	NULL
research	NULL
will	NULL
need	NULL
to	NULL
be	NULL
performed	NULL
to	NULL
dissert	NULL
the	NULL
precise	NULL
molecular	NULL
pathways	NULL
involved	NULL
in	NULL
PPAR-y	NULL
agonist-in-duced	NULL
signal	NULL
transduction	NULL
.	NULL

Finally	NULL
,	NULL
we	NULL
suggest	NULL
a	NULL
scenario	NULL
in	NULL
which	NULL
alteration	NULL
of	NULL
the	NULL
15d-PGJ	NULL
,	NULL
/PGF	NULL
;	NULL
,	NULL
,	NULL
balance	NULL
could	NULL
affect	NULL
the	NULL
development	NULL
of	NULL
B	NULL
cell	NULL
lymphomas	NULL
.	NULL

Environments	NULL
rich	NULL
in	NULL
PGF	NULL
,	NULL
,	NULL
,	NULL
would	NULL
blunt	NULL
the	NULL
ability	NULL
of	NULL
15d-PGJ	NULL
,	NULL
to	NULL
kill	NULL
B-lineage	NULL
cells	NULL
.	NULL

Alternatively	NULL
,	NULL
the	NULL
use	NULL
of	NULL
15d-PGJ	NULL
,	NULL
or	NULL
its	NULL
analogues	NULL
in	NULL
the	NULL
appropriate	NULL
prostanoid	NULL
milieu	NULL
may	NULL
be	NULL
useful	NULL
as	NULL
a	NULL
therapy	NULL
for	NULL
B-lineage	NULL
malignancies	NULL
.	NULL

Acknowledgments	NULL
We	NULL
thank	NULL
Parke-Davis	NULL
for	NULL
the	NULL
generous	NULL
gift	NULL
of	NULL
troglitazone	NULL
.	NULL

References	NULL
1	NULL
.	NULL

Lewis	NULL
,	NULL
R.	NULL
A.	NULL
,	NULL
N.	NULL
A.	NULL
Sorte	NULL
,	NULL
P.	NULL
T.	NULL
Diamond	NULL
,	NULL
K.	NULL
F.	NULL
Austen	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Oates	NULL
,	NULL
and	NULL
L.	NULL
J.	NULL
Roberts	NULL
.	NULL

1982	NULL
.	NULL

Prostaglandin	NULL
D	NULL
,	NULL
generation	NULL
after	NULL
activation	NULL
of	NULL
rat	NULL
human	NULL
mast	NULL
cells	NULL
with	NULL
anti-IgE	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

129:1627	NULL
.	NULL

2	NULL
.	NULL

Urade	NULL
,	NULL
Y.	NULL
,	NULL
M.	NULL
Ujihara	NULL
,	NULL
Y.	NULL
Horiguchi	NULL
,	NULL
K.	NULL
Ikai	NULL
,	NULL
and	NULL
O.	NULL
Hayaishi	NULL
.	NULL

1989	NULL
.	NULL

The	NULL
major	NULL
source	NULL
of	NULL
endogenous	NULL
prostaglandin	NULL
D	NULL
;	NULL
,	NULL
production	NULL
is	NULL
likely	NULL
antigen	NULL
presenting	NULL
cells	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

143:2982	NULL
.	NULL

3	NULL
.	NULL

Kojima	NULL
,	NULL
A.	NULL
,	NULL
M.	NULL
Shiraki	NULL
,	NULL
R.	NULL
Takahashi	NULL
,	NULL
H.	NULL
Orimo	NULL
,	NULL
I.	NULL
Morita	NULL
,	NULL
and	NULL
S.	NULL
Murota	NULL
.	NULL

1980	NULL
.	NULL

Prostaglandin	NULL
D	NULL
;	NULL
is	NULL
the	NULL
major	NULL
prostaglandin	NULL
of	NULL
arachidonic	NULL
acid	NULL
metabolism	NULL
in	NULL
rat	NULL
bone	NULL
marrow	NULL
homogenate	NULL
.	NULL

Prostaglandins	NULL
20:171	NULL
.	NULL

4	NULL
.	NULL

Ujihara	NULL
,	NULL
M.	NULL
,	NULL
Y.	NULL
Urade	NULL
,	NULL
N.	NULL
Eguchi	NULL
,	NULL
H.	NULL
Hayashi	NULL
,	NULL
K.	NULL
Ikai	NULL
,	NULL
and	NULL
O.	NULL
Hayaishi	NULL
.	NULL

1988	NULL
.	NULL

Prostaglandin	NULL
D	NULL
;	NULL
,	NULL
formation	NULL
and	NULL
characterization	NULL
of	NULL
its	NULL
synthetases	NULL
in	NULL
various	NULL
tissues	NULL
of	NULL
adult	NULL
rats	NULL
.	NULL

Arch	NULL
.	NULL

Biochem	NULL
.	NULL

Biophys	NULL
.	NULL

260:521	NULL
.	NULL

5	NULL
.	NULL

Fukushima	NULL
,	NULL
M.	NULL
1992	NULL
.	NULL

Biological	NULL
activities	NULL
and	NULL
mechanisms	NULL
of	NULL
action	NULL
of	NULL
PGJ	NULL
,	NULL
and	NULL
related	NULL
compounds	NULL
:	NULL
an	NULL
update	NULL
.	NULL

Prostaglandins	NULL
Leukotrienes	NULL
Essen	NULL
.	NULL

Fatty	NULL
Acids	NULL
47:1	NULL
.	NULL

6	NULL
.	NULL

Hirata	NULL
,	NULL
M.	NULL
,	NULL
A.	NULL
Kakizuka	NULL
,	NULL
M.	NULL
Aizawa	NULL
,	NULL
F.	NULL
Ushikubi	NULL
,	NULL
and	NULL
S.	NULL
Narumiya	NULL
.	NULL

1994	NULL
.	NULL

Molecular	NULL
characterization	NULL
of	NULL
a	NULL
mouse	NULL
prostaglandin	NULL
D	NULL
receptor	NULL
and	NULL
functional	NULL
expression	NULL
of	NULL
the	NULL
cloned	NULL
gene	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
91:11192	NULL
.	NULL

7	NULL
.	NULL

Narumiya	NULL
,	NULL
S.	NULL
,	NULL
K.	NULL
Ohno	NULL
,	NULL
M.	NULL
Fukushima	NULL
,	NULL
and	NULL
M.	NULL
Fujiwara	NULL
.	NULL

1987	NULL
.	NULL

Site	NULL
and	NULL
mechanism	NULL
of	NULL
growth	NULL
inhibition	NULL
by	NULL
prostaglandins	NULL
.	NULL

III	NULL
.	NULL

Distribution	NULL
and	NULL
binding	NULL
of	NULL
prostaglandin	NULL
A	NULL
;	NULL
and	NULL
A'-prostaglandin	NULL
J	NULL
,	NULL
in	NULL
nuclei	NULL
.	NULL

J.	NULL
Pharmacol	NULL
.	NULL

Exp	NULL
.	NULL

Ther	NULL
.	NULL

242:306	NULL
.	NULL

8	NULL
.	NULL

Schoonjans	NULL
,	NULL
K.	NULL
,	NULL
B.	NULL
Staels	NULL
,	NULL
and	NULL
J.	NULL
Auwerx	NULL
.	NULL

1996	NULL
.	NULL

The	NULL
peroxisome	NULL
proliferator	NULL
activated	NULL
receptors	NULL
(	NULL
PPARS	NULL
)	NULL
and	NULL
their	NULL
effects	NULL
on	NULL
lipid	NULL
metabolism	NULL
and	NULL
adipocyte	NULL
differentiation	NULL
.	NULL

Biochim	NULL
.	NULL

Biophys	NULL
.	NULL

Acta	NULL
1302:93	NULL
.	NULL

9	NULL
.	NULL

Kliewer	NULL
,	NULL
S.	NULL
A.	NULL
,	NULL
J.	NULL
M.	NULL
Lenhard	NULL
,	NULL
T.	NULL
M.	NULL
Willson	NULL
,	NULL
I.	NULL
Patel	NULL
,	NULL
D.	NULL
C.	NULL
Morris	NULL
,	NULL
and	NULL
J.	NULL
M.	NULL
Lehmann	NULL
.	NULL

1995	NULL
.	NULL

A	NULL
prostaglandin	NULL
J	NULL
,	NULL
metabolite	NULL
binds	NULL
peroxisome	NULL
proliferator-activated	NULL
receptor	NULL
-y	NULL
and	NULL
promotes	NULL
adipocyte	NULL
differentiation	NULL
.	NULL

Cell	NULL
83:813	NULL
.	NULL

10	NULL
.	NULL

Jiang	NULL
,	NULL
C.	NULL
,	NULL
A.	NULL
T.	NULL
Ting	NULL
,	NULL
and	NULL
B	NULL
.	NULL

Seed	NULL
.	NULL

1998	NULL
.	NULL

PPAR-y	NULL
agonists	NULL
inhibit	NULL
production	NULL
of	NULL
monocyte	NULL
inflammatory	NULL
cytokines	NULL
.	NULL

Nature	NULL
391:82	NULL
.	NULL

11	NULL
.	NULL

Ricote	NULL
,	NULL
M.	NULL
,	NULL
A.	NULL
C.	NULL
Li	NULL
,	NULL
T.	NULL
M.	NULL
Willson	NULL
,	NULL
C.	NULL
J.	NULL
Kelly	NULL
,	NULL
and	NULL
C.	NULL
K.	NULL
Glass	NULL
.	NULL

1998	NULL
.	NULL

The	NULL
peroxisome	NULL
proliferator-activated	NULL
receptor-y	NULL
is	NULL
a	NULL
negative	NULL
regulator	NULL
of	NULL
macro-phage	NULL
activation	NULL
.	NULL

Nature	NULL
391:79	NULL
.	NULL

12	NULL
.	NULL

Greene	NULL
,	NULL
M.	NULL
E.	NULL
,	NULL
B.	NULL
Blumberg	NULL
,	NULL
O.	NULL
W.	NULL
McBride	NULL
,	NULL
H.	NULL
F.	NULL
Yi	NULL
,	NULL
K.	NULL
Kronquist	NULL
,	NULL
K.	NULL
Kwan	NULL
,	NULL
L.	NULL
Hsich	NULL
,	NULL
G.	NULL
Greene	NULL
,	NULL
and	NULL
S.	NULL
D.	NULL
Nimer	NULL
.	NULL

1995	NULL
.	NULL

Isolation	NULL
of	NULL
the	NULL
human	NULL
peroxisome	NULL
13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

23	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26	NULL
.	NULL

27	NULL
.	NULL

28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

32	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

PPAR-y	NULL
ON	NULL
B-LINEAGE	NULL
CELLS	NULL
proliferator	NULL
activated	NULL
receptor	NULL
y	NULL
cDNA	NULL
:	NULL
expression	NULL
in	NULL
hematopoietic	NULL
cells	NULL
and	NULL
chromosomal	NULL
mapping	NULL
.	NULL

Gene	NULL
Express	NULL
.	NULL

4:281	NULL
.	NULL

DuBois	NULL
,	NULL
R.	NULL
N.	NULL
,	NULL
R.	NULL
Gupta	NULL
,	NULL
J.	NULL
Brockman	NULL
,	NULL
B.	NULL
S.	NULL
Reddy	NULL
,	NULL
S.	NULL
L.	NULL
Krakow	NULL
,	NULL
and	NULL
M.	NULL
A.	NULL
Lazar	NULL
.	NULL

1998	NULL
.	NULL

The	NULL
nuclear	NULL
eicosanoid	NULL
receptor	NULL
,	NULL
PPAR	NULL
,	NULL
is	NULL
aberrantly	NULL
expressed	NULL
in	NULL
colonic	NULL
cancers	NULL
.	NULL

Carcinogenesis	NULL
19:49	NULL
,	NULL
Clark	NULL
,	NULL
R.	NULL
B.	NULL
,	NULL
D.	NULL
Bishop-Bailey	NULL
,	NULL
T.	NULL
Estrada-Hernandez	NULL
,	NULL
T.	NULL
Hla	NULL
,	NULL
L.	NULL
Puddington	NULL
,	NULL
and	NULL
S.	NULL
J.	NULL
Padula	NULL
,	NULL
2000	NULL
.	NULL

The	NULL
nuclear	NULL
receptor	NULL
PPAR-y	NULL
and	NULL
immunoregulation	NULL
:	NULL
PPARy	NULL
mediates	NULL
inhibition	NULL
of	NULL
helper	NULL
T	NULL
cell	NULL
responses	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

164:1364	NULL
.	NULL

Marx	NULL
,	NULL
N.	NULL
,	NULL
U.	NULL
Schonbeck	NULL
,	NULL
M.	NULL
A.	NULL
Lazar	NULL
,	NULL
P.	NULL
Libby	NULL
,	NULL
and	NULL
J.	NULL
Plutzky	NULL
.	NULL

1998	NULL
.	NULL

Peroxisome	NULL
proliferator-activated	NULL
receptor	NULL
-y	NULL
activators	NULL
gene	NULL
expression	NULL
and	NULL
migration	NULL
in	NULL
human	NULL
vascular	NULL
smooth	NULL
muscle	NULL
cells	NULL
.	NULL

Circ	NULL
.	NULL

Res	NULL
.	NULL

83:1097	NULL
.	NULL

Marx	NULL
,	NULL
N.	NULL
,	NULL
T.	NULL
Bourcier	NULL
,	NULL
G.	NULL
K.	NULL
Sukhova	NULL
,	NULL
P.	NULL
Libby	NULL
,	NULL
and	NULL
J.	NULL
Plutzky	NULL
.	NULL

1999	NULL
.	NULL

PPAR	NULL
gamma	NULL
activation	NULL
in	NULL
human	NULL
endothelial	NULL
cells	NULL
increases	NULL
plasminogen	NULL
activator	NULL
inhibitor	NULL
type-1	NULL
expression	NULL
:	NULL
PPAR	NULL
-y	NULL
as	NULL
a	NULL
potential	NULL
mediator	NULL
in	NULL
vascular	NULL
disease	NULL
.	NULL

Artherioscler	NULL
.	NULL

Thromb	NULL
.	NULL

Vasc	NULL
.	NULL

Biol	NULL
.	NULL

19:546	NULL
.	NULL

Scott	NULL
,	NULL
D.	NULL
W.	NULL
1993	NULL
.	NULL

B	NULL
lymphoma	NULL
models	NULL
for	NULL
tolerance	NULL
:	NULL
the	NULL
good	NULL
,	NULL
the	NULL
bad	NULL
and	NULL
the	NULL
apoptotic	NULL
.	NULL

Immunomethods	NULL
2:105	NULL
.	NULL

Fedyk	NULL
,	NULL
E.	NULL
R.	NULL
,	NULL
J.	NULL
M.	NULL
Ripper	NULL
,	NULL
and	NULL
R.	NULL
P.	NULL
Phipps	NULL
.	NULL

1996	NULL
.	NULL

A	NULL
molecular	NULL
analysis	NULL
of	NULL
PGE	NULL
receptor	NULL
expression	NULL
by	NULL
mouse	NULL
B	NULL
lymphocytes	NULL
:	NULL
coexpression	NULL
of	NULL
EP	NULL
;	NULL
,	NULL
EP	NULL
;	NULL
,	NULL
EP	NULL
;	NULL
,	NULL
and	NULL
EP	NULL
,	NULL
.	NULL

Mol	NULL
.	NULL

Immunol	NULL
.	NULL

33:33	NULL
.	NULL

Fukushima	NULL
,	NULL
M.	NULL
,	NULL
H.	NULL
Sasaki	NULL
,	NULL
and	NULL
S.	NULL
Fukushima	NULL
.	NULL

1994	NULL
.	NULL

Prostaglandin	NULL
J	NULL
;	NULL
and	NULL
related	NULL
compounds	NULL
.	NULL

Ann	NULL
.	NULL

NY	NULL
Acad	NULL
.	NULL

Sci	NULL
.	NULL

744:161	NULL
.	NULL

Stein	NULL
,	NULL
S.	NULL
H.	NULL
,	NULL
and	NULL
R.	NULL
P.	NULL
Phipps	NULL
.	NULL

1991	NULL
.	NULL

Antigen-specific	NULL
IgG	NULL
,	NULL
,	NULL
production	NULL
in	NULL
response	NULL
to	NULL
prostaglandin	NULL
E	NULL
,	NULL
,	NULL
immune	NULL
complexes	NULL
,	NULL
and	NULL
IFN-y	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

147:2500	NULL
.	NULL

Defranco	NULL
,	NULL
A.	NULL
L.	NULL
,	NULL
E.	NULL
S.	NULL
Raveche	NULL
,	NULL
R.	NULL
Asofsky	NULL
,	NULL
and	NULL
W.	NULL
E.	NULL
Paul	NULL
.	NULL

1982	NULL
.	NULL

Frequency	NULL
of	NULL
B	NULL
lymphocytes	NULL
responsive	NULL
to	NULL
anti-immunoglobulin	NULL
.	NULL

J.	NULL
Exp	NULL
.	NULL

Med	NULL
.	NULL

155:1523	NULL
.	NULL

Roper	NULL
,	NULL
R.	NULL
L.	NULL
,	NULL
and	NULL
R.	NULL
P.	NULL
Phipps	NULL
.	NULL

1992	NULL
.	NULL

Prostaglandin	NULL
E	NULL
,	NULL
and	NULL
cAMP	NULL
inhibit	NULL
B	NULL
lymphocytes	NULL
activation	NULL
and	NULL
simultaneously	NULL
promote	NULL
IgE	NULL
and	NULL
IgG	NULL
,	NULL
synthesis	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

149:2984	NULL
.	NULL

Gavrieli	NULL
,	NULL
Y.	NULL
,	NULL
Y.	NULL
Sherman	NULL
,	NULL
and	NULL
S.	NULL
A.	NULL
Ben-Sasson	NULL
.	NULL

1992	NULL
.	NULL

Identification	NULL
of	NULL
programmed	NULL
cell	NULL
death	NULL
in	NULL
situ	NULL
via	NULL
specific	NULL
labeling	NULL
of	NULL
nuclear	NULL
DNA	NULL
fragmentation	NULL
.	NULL

J	NULL
.	NULL

Cell	NULL
Biol	NULL
.	NULL

119:493	NULL
.	NULL

Cao	NULL
,	NULL
J.	NULL
H.	NULL
,	NULL
H.	NULL
Wang	NULL
,	NULL
Y.	NULL
Zhang	NULL
,	NULL
H.	NULL
Lin	NULL
,	NULL
R.	NULL
P.	NULL
Phipps	NULL
,	NULL
and	NULL
T.	NULL
J.	NULL
Smith	NULL
.	NULL

1998	NULL
.	NULL

Activation	NULL
of	NULL
human	NULL
orbit	NULL
fibroblasts	NULL
through	NULL
CD40	NULL
engagement	NULL
results	NULL
in	NULL
a	NULL
dramatic	NULL
induction	NULL
of	NULL
hyaluronan	NULL
synthesis	NULL
and	NULL
prostaglandin	NULL
endoperoxide	NULL
H	NULL
synthase-2	NULL
expression	NULL
.	NULL

J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

273:29615	NULL
.	NULL

Forman	NULL
,	NULL
B.	NULL
M.	NULL
,	NULL
P.	NULL
Tontonoz	NULL
,	NULL
J.	NULL
Chen	NULL
,	NULL
R.	NULL
P.	NULL
Brun	NULL
,	NULL
B.	NULL
M.	NULL
Spiegelman	NULL
,	NULL
and	NULL
R.	NULL
M.	NULL
Evans	NULL
.	NULL

1995	NULL
.	NULL

15-Deoxy-A'*	NULL
``	NULL
``	NULL
-	NULL
prostaglandin	NULL
J	NULL
;	NULL
is	NULL
a	NULL
ligand	NULL
for	NULL
the	NULL
adipocyte	NULL
determination	NULL
factor	NULL
PPARy	NULL
.	NULL

Cell	NULL
83:803	NULL
.	NULL

Adams	NULL
,	NULL
M.	NULL
,	NULL
C.	NULL
T.	NULL
Montangue	NULL
,	NULL
J	NULL
.	NULL

B.	NULL
Prins	NULL
,	NULL
J.	NULL
C.	NULL
Holder	NULL
,	NULL
S.	NULL
A.	NULL
Smith	NULL
,	NULL
L.	NULL
Sanders	NULL
,	NULL
J.	NULL
E.	NULL
Digby	NULL
,	NULL
C.	NULL
P.	NULL
Sewter	NULL
,	NULL
M.	NULL
A.	NULL
Lazar	NULL
,	NULL
V.	NULL
Chatterjee	NULL
,	NULL
et	NULL
al	NULL
.	NULL

1997	NULL
.	NULL

Activators	NULL
of	NULL
peroxisome	NULL
proliferator-activated	NULL
receptor	NULL
-y	NULL
have	NULL
depot-specific	NULL
effects	NULL
on	NULL
human	NULL
preadipocyte	NULL
differentiation	NULL
.	NULL

J.	NULL
Clin	NULL
.	NULL

Invest	NULL
.	NULL

100:3149	NULL
.	NULL

Keller	NULL
,	NULL
H.	NULL
,	NULL
C.	NULL
Dreyer	NULL
,	NULL
J.	NULL
Medin	NULL
,	NULL
A.	NULL
Mahfoudi	NULL
,	NULL
K.	NULL
Ozato	NULL
,	NULL
and	NULL
W.	NULL
Wahli	NULL
.	NULL

1993	NULL
.	NULL

Fatty	NULL
acids	NULL
and	NULL
retinoids	NULL
control	NULL
lipid	NULL
metabolism	NULL
through	NULL
activation	NULL
of	NULL
peroxisome	NULL
proliferator-activated	NULL
receptor-retinoid	NULL
X	NULL
receptor	NULL
heterodimers	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
90:2160	NULL
.	NULL

DiRenzo	NULL
,	NULL
J.	NULL
,	NULL
M.	NULL
Soderstrom	NULL
,	NULL
R.	NULL
Kurokawa	NULL
,	NULL
M.	NULL
H.	NULL
Ogliastro	NULL
,	NULL
M.	NULL
Ricote	NULL
,	NULL
S.	NULL
Ingrey	NULL
,	NULL
A.	NULL
Horlein	NULL
,	NULL
M.	NULL
G.	NULL
Rosenfeld	NULL
,	NULL
and	NULL
C.	NULL
K.	NULL
Glass	NULL
.	NULL

1997	NULL
.	NULL

Peroxisome	NULL
proliferator-activated	NULL
receptors	NULL
and	NULL
retinoic	NULL
acid	NULL
receptors	NULL
differentially	NULL
control	NULL
the	NULL
interactions	NULL
of	NULL
retinoid	NULL
X	NULL
receptor	NULL
heterodimers	NULL
with	NULL
ligands	NULL
,	NULL
coactivators	NULL
,	NULL
and	NULL
core-pressors	NULL
.	NULL

Mol	NULL
Cell	NULL
.	NULL

Biol	NULL
.	NULL

17:2166	NULL
.	NULL

Vermes	NULL
,	NULL
I.	NULL
,	NULL
C.	NULL
Haanen	NULL
,	NULL
H.	NULL
Steffens-Nakken	NULL
,	NULL
and	NULL
C.	NULL
Reutelingsperger	NULL
.	NULL

1995	NULL
.	NULL

A	NULL
novel	NULL
assay	NULL
for	NULL
apoptosis	NULL
flow	NULL
cytometric	NULL
detection	NULL
of	NULL
phosphatidylserine	NULL
expression	NULL
on	NULL
early	NULL
apoptotic	NULL
cells	NULL
using	NULL
fluorescein	NULL
labeled	NULL
annexin	NULL
V.	NULL
J.	NULL
Immunol	NULL
.	NULL

Methods	NULL
184:39	NULL
.	NULL

Reginato	NULL
,	NULL
M.	NULL
J.	NULL
,	NULL
S.	NULL
L.	NULL
Krakow	NULL
,	NULL
S.	NULL
T.	NULL
Bailey	NULL
,	NULL
and	NULL
M.	NULL
A.	NULL
Lazar	NULL
.	NULL

1998	NULL
.	NULL

Prostaglandins	NULL
promote	NULL
and	NULL
block	NULL
adipogenesis	NULL
through	NULL
opposing	NULL
effects	NULL
on	NULL
peroxisome	NULL
proliferator-activated	NULL
receptor	NULL
y.	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

273:1855	NULL
.	NULL

Braissant	NULL
,	NULL
O.	NULL
,	NULL
F.	NULL
Foufelle	NULL
,	NULL
C.	NULL
Scotto	NULL
,	NULL
M.	NULL
Dauca	NULL
,	NULL
and	NULL
W.	NULL
Wahli	NULL
.	NULL

1996	NULL
.	NULL

Differential	NULL
expression	NULL
of	NULL
peroxisome	NULL
proliferator-activated	NULL
receptors	NULL
(	NULL
PPARs	NULL
)	NULL
:	NULL
tissue	NULL
distribution	NULL
of	NULL
PPAR-a	NULL
,	NULL
-B	NULL
,	NULL
and	NULL
-y	NULL
in	NULL
the	NULL
adult	NULL
rat	NULL
.	NULL

Endocrinology	NULL
137:354	NULL
.	NULL

Phipps	NULL
,	NULL
R.	NULL
P.	NULL
,	NULL
S.	NULL
H.	NULL
Stein	NULL
,	NULL
and	NULL
R.	NULL
L.	NULL
Roper	NULL
.	NULL

1991	NULL
.	NULL

A	NULL
new	NULL
view	NULL
of	NULL
prostaglandin	NULL
E	NULL
regulation	NULL
of	NULL
the	NULL
immune	NULL
response	NULL
.	NULL

Immunol	NULL
.	NULL

Today	NULL
12:349	NULL
.	NULL

Fedyk	NULL
,	NULL
E.	NULL
R.	NULL
,	NULL
and	NULL
R.	NULL
P.	NULL
Phipps	NULL
.	NULL

1996	NULL
.	NULL

Prostaglandin	NULL
E	NULL
;	NULL
receptors	NULL
of	NULL
the	NULL
EP	NULL
,	NULL
and	NULL
EP	NULL
,	NULL
subtypes	NULL
regulate	NULL
activation	NULL
and	NULL
differentiation	NULL
of	NULL
mouse	NULL
B	NULL
lymphocytes	NULL
to	NULL
IgE-secreting	NULL
cells	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
93:10978	NULL
.	NULL

Potter	NULL
,	NULL
M.	NULL
,	NULL
J.	NULL
Wax	NULL
,	NULL
and	NULL
G.	NULL
M.	NULL
Jones	NULL
.	NULL

1997	NULL
.	NULL

Indomethacin	NULL
is	NULL
potent	NULL
inhibitor	NULL
of	NULL
pristane	NULL
and	NULL
plastic	NULL
disc	NULL
induced	NULL
plasmacytomagenesis	NULL
in	NULL
a	NULL
hypersusceptible	NULL
BALB/c	NULL
congenic	NULL
strain	NULL
.	NULL

Blood	NULL
90:260	NULL
.	NULL

Hinson	NULL
,	NULL
R.	NULL
M.	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
Williams	NULL
,	NULL
and	NULL
E.	NULL
Shacter	NULL
.	NULL

1996	NULL
.	NULL

Elevated	NULL
interleukin	NULL
6	NULL
is	NULL
induced	NULL
by	NULL
prostaglandin	NULL
E	NULL
;	NULL
in	NULL
a	NULL
murine	NULL
model	NULL
of	NULL
inflammation	NULL
:	NULL
possible	NULL
role	NULL
of	NULL
cyclooxygenase-2	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
93:4885	NULL
.	NULL

Petrova	NULL
,	NULL
T.	NULL
V.	NULL
,	NULL
K.	NULL
T.	NULL
Akama	NULL
,	NULL
and	NULL
L.	NULL
J	NULL
.	NULL

Van	NULL
Eldik	NULL
.	NULL

1999	NULL
.	NULL

Cyclopentenone	NULL
prostaglandins	NULL
suppress	NULL
activation	NULL
of	NULL
microglia	NULL
:	NULL
down-regulation	NULL
of	NULL
inducible	NULL
nitric-oxide	NULL
synthetase	NULL
by	NULL
15d-deoxy-A12,14-prostaglandin	NULL
J	NULL
;	NULL
.	NULL

Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

USA	NULL
96:4668	NULL
.	NULL

Vaidya	NULL
,	NULL
S.	NULL
,	NULL
E.	NULL
P.	NULL
Somers	NULL
,	NULL
S.	NULL
D.	NULL
Wright	NULL
,	NULL
P.	NULL
A.	NULL
Detmers	NULL
,	NULL
and	NULL
V.	NULL
S.	NULL
Bansal	NULL
.	NULL

1999	NULL
.	NULL

15-Deoxy-A12,14-prostaglandin	NULL
J	NULL
;	NULL
,	NULL
inhibits	NULL
the	NULL
B	NULL
;	NULL
integrin-dependent	NULL
oxidative	NULL
burst	NULL
:	NULL
involvement	NULL
of	NULL
a	NULL
mechanism	NULL
distinct	NULL
from	NULL
peroxisome	NULL
proliferator-activated	NULL
receptor	NULL
-y	NULL
ligation	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

163:6187	NULL
.	NULL

6107	NULL
'01	NULL
Aepy	NULL
uo	NULL
isan	NULL
$	NULL
4q	NULL
310	NULL
founwurrf'mmm//	NULL
:	NULL
dyy	NULL
wo	NULL
papeojumoG	NULL

